supp.fit

Docosahexaenoic Acid: study protocols

667 study groups say how much Docosahexaenoic Acid participants took a day. These are the doses the studies gave. They are not a recommendation.

Docosahexaenoic Acid: what the research found →

Dose per serving from products

6,506 products in our catalogue print how much Docosahexaenoic Acid a serving holds.

Most common: 100 mg to 250 mg, 34% of 6,506 products.

Dose per servingProducts
25 mg or less
253
25 mg to 50 mg
521
50 mg to 100 mg
730
100 mg to 250 mg
2,211
250 mg to 500 mg
1,779
500 mg to 1 g
937
over 1 g
75

Dose per serving from research

635 study groups in 500 studies say how much Docosahexaenoic Acid participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 500 mg to 1 g, 27% of 635 study groups.

Daily doseStudy groups
100 mg or less
23
100 mg to 250 mg
81
250 mg to 500 mg
131
500 mg to 1 g
169
1 g to 2.5 g
168
2.5 g to 5 g
55
over 5 g
8

Commonly used together

438 of 667 study groups took Docosahexaenoic Acid with something else. Shown: what 3 or more different studies gave. The 10 most common of 24.

What was given together, not what works together.

Taken withStudy groups
Omega-3 Fatty Acids
244
Fish Oil
124
eicosapentaenoic acid (EPA)
56
EPA
42
Eicosapentaenoic Acid
36
Arachidonic Acid
27
Vitamin E
18
Choline
12
Folic Acid
12
Lutein
12

667 study groups

Study
Racial disparity in efficacy of docosahexaenoic acid supplementation for prevention of preterm birth: secondary analysis from a randomized, double-blind trial
2024 · low-dose DHA · Pregnant individuals enrolled before 20 weeks’ gestation; analyzed by Black and non-Black race/ethnicity
200 mg—492
Higher-Dose DHA Supplementation Modulates Immune Responses in Pregnancy and Is Associated with Decreased Preterm Birth
2021 · 200 mg group · Pregnant women; age and sex beyond pregnancy not specified
200 mg—437
A randomized trial of docosahexaenoic acid supplementation during the third trimester of pregnancy
2003 · 133 mg DHA group · Pregnant women enrolled between the 24th and 28th week of pregnancy
133 mg——
Docosahexaenoic acid (DHA) intake estimated from a 7-question survey identifies pregnancies most likely to benefit from high-dose DHA supplementation
2023 · 200 mg/day DHA group · Pregnant adults aged 18 years or older with a singleton pregnancy, enrolled before 20 weeks’ gestation
200 mg——
Effects of docosahexaenoic acid supplementation during pregnancy on gestational age and size at birth: randomized, double-blind, placebo-controlled trial in Mexico
2010 · DHA group · Pregnant women aged 18 to 35 years
400 mg—547
Early and late preterm birth rates in participants adherent to randomly assigned high dose docosahexaenoic acid (DHA) supplementation in pregnancy
2023 · 200 mg DHA group · Pregnant adults aged 18 or older, enrolled at 12–20 weeks’ gestation
200 mg—524
Biological safety assessment of docosahexaenoic acid supplementation in a randomized clinical trial for X-linked retinitis pigmentosa
2003 · docosahexaenoic acid · Male patients with X-linked retinitis pigmentosa; mean age 16 years
400 mg4 years—
The Effect of Omega-3 Docosahexaenoic Acid Supplementation on Gestational Length: Randomized Trial of Supplementation Compared to Nutrition Education for Increasing n-3 Intake from Foods
2015 · 300 mg DHA · Pregnant women aged 18 years or older with singleton pregnancies, enrolled at 16–20 weeks’ gestation; low-income antenatal clinic population
300 mg——
Growth patterns in infants born to women with pregestational overweight/obesity supplemented with docosahexaenoic acid during pregnancy
2024 · PGO-200 group · Pregnant women with pregestational overweight or obesity; age and sex beyond pregnancy not specified
200 mg—81
The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease
2013 · DHA 250 mg/day · Children with non-alcoholic fatty liver disease (age range and sex not stated)
250 mg2 years20
[Docosahexaenoic acid benefits on growth and body composition of septic neonates. Randomized trial]
2025 · DHA group · Term and preterm neonates with late-onset sepsis who required surgery
100 mg2 weeks18
Docosahexaenoic acid administered in the acute phase protects the nutritional status of septic neonates
2006 · DHA group · Neonates who developed sepsis after a surgical procedure
100 mg2 weeks16
DHA Supplementation During Pregnancy Enhances Maternal Vagally Mediated Cardiac Autonomic Control in Humans
2023 · 200 mg/d DHA · Pregnant women aged 18 years or older with singleton pregnancies, enrolled at 12–20 weeks of gestation
200 mg——
Effects of Prenatal DHA Dose on Infant Visual Attention
2025 · 200 mg/day DHA group · Pregnant women; maternal age and specific eligibility condition not reported
200 mg——
Docosahexaenoic Acid and Bronchopulmonary Dysplasia in Preterm Infants
2017 · DHA group · Preterm infants born before 29 weeks of gestation
60 mg/kg—592
Racial disparity in efficacy of docosahexaenoic acid supplementation for prevention of preterm birth: secondary analysis from a randomized, double-blind trial
2024 · high-dose DHA · Pregnant individuals enrolled before 20 weeks’ gestation; analyzed by Black and non-Black race/ethnicity
1 g—540
Efficacy of Docosahexaenoic Acid for the Prevention of Necrotizing Enterocolitis in Preterm Infants: A Randomized Clinical Trial
2021 · DHA-group · Preterm newborn infants weighing 1000–1500 g, at risk of necrotizing enterocolitis
75 mg/kg2 weeks100
Enteral Docosahexaenoic Acid and Retinopathy of Prematurity: A Randomized Clinical Trial
2019 · DHA group · Preterm infants with birth weight 1000 g to less than 1500 g
75 mg/kg2 weeks55
A randomized trial of docosahexaenoic acid supplementation during the third trimester of pregnancy
2003 · 33 mg DHA group · Pregnant women enrolled between the 24th and 28th week of pregnancy
33 mg——
The Effect of Omega-3 Docosahexaenoic Acid Supplementation on Gestational Length: Randomized Trial of Supplementation Compared to Nutrition Education for Increasing n-3 Intake from Foods
2015 · 600 mg DHA · Pregnant women aged 18 years or older with singleton pregnancies, enrolled at 16–20 weeks’ gestation; low-income antenatal clinic population
600 mg——
Docosahexaenoic acid supplementation (DHA) and the return on investment for pregnancy outcomes
2016 · DHA group · Pregnant women; age not stated; no specific condition stated
600 mg——
Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)
2018 · SC411 20 mg DHA/kg per day · Children aged 5–17 years with sickle cell disease
20 mg/kg4 weeks—
Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)
2018 · SC411 36 mg DHA/kg per day · Children aged 5–17 years with sickle cell disease
36 mg/kg4 weeks—
Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)
2018 · SC411 60 mg DHA/kg per day · Children aged 5–17 years with sickle cell disease
60 mg/kg4 weeks—
Dose-response relationship between docosahexaenoic acid (DHA) intake and lower rates of early preterm birth, low birth weight and very low birth weight
2018 · 600 mg DHA/d group · Pregnant women with healthy singleton pregnancies, recruited before 20 weeks’ gestation
600 mg——
Clinical Efficacy and Biological Regulations of ω-3 PUFA-Derived Endocannabinoids in Major Depressive Disorder
2019 · DHA group · Adults with major depressive disorder
1.4 g12 weeks—
Docosahexaenoic acid (DHA) intake estimated from a 7-question survey identifies pregnancies most likely to benefit from high-dose DHA supplementation
2023 · 800 mg/day DHA group (PANDA trial) · Pregnant adults aged 18 years or older with a singleton pregnancy, enrolled before 20 weeks’ gestation
800 mg——
Docosahexaenoic acid (DHA) intake estimated from a 7-question survey identifies pregnancies most likely to benefit from high-dose DHA supplementation
2023 · 1000 mg/day DHA group (ADORE trial) · Pregnant adults aged 18 years or older with a singleton pregnancy, enrolled before 20 weeks’ gestation
1 g——
Prenatal Docosahexaenoic Acid Supplementation and Offspring Development at 18 Months: Randomized Controlled Trial
2015 · DHA · Pregnant women aged 18–35 years, enrolled at 18–22 weeks of gestation
400 mg—365
Maternal FADS2 single nucleotide polymorphism modified the impact of prenatal docosahexaenoic acid (DHA) supplementation on child neurodevelopment at 5 years: Follow-up of a randomized clinical trial
2021 · DHA intervention group · Pregnant women enrolled at 18–22 weeks of gestation; maternal age range and health conditions not specified
400 mg—316
Short-Term Omega 3 Fatty Acids Treatment for Dry Eye in Young and Middle-Aged Visual Display Terminal Users
2016 · O3FA group · Young and middle-aged visual display terminal users with dry eye symptoms
240 mg45 days256
Essential n-3 fatty acids in pregnant women and early visual acuity maturation in term infants
2008 · DHA · Pregnant women, from 16 weeks’ gestation until delivery
400 mg—67
Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and auto-immunity
2009 · fish-oil intervention group · Adults with metabolic syndrome; mean age 52.9 years; sex not specified
120 mg26 weeks60
Pilot study on the effect of supplementation with long-chain ω-3 polyunsaturated fatty acids on body composition in children with acute lymphoblastic leukemia: randomized clinical trial
2023 · LCPUFA-ω3 group · Children aged 3–13 years with newly diagnosed acute lymphoblastic leukemia
225 mg90 days36
Short-term consumption of oral omega-3 and dry eye syndrome
2013 · treatment group · Patients aged 45–90 years with dry eye symptoms
240 mg30 days33
Maturation of visual acuity is accelerated in breast-fed term infants fed baby food containing DHA-enriched egg yolk
2004 · DHA-enriched egg-yolk baby food group · Breast-fed infants assigned at 6 months of age
83 mg26 weeks25
A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa
2004 · +DHA group · Male patients with X-linked retinitis pigmentosa, ages 4–38 years (mean age 16 years)
400 mg4 years23
The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease
2013 · DHA 500 mg/day · Children with non-alcoholic fatty liver disease (age range and sex not stated)
500 mg2 years20
Eicosapentaenoic Acid-Rich Fish Oil Supplementation Inhibits the Decrease in Concentric Work Output and Muscle Swelling of the Elbow Flexors
2019 · EPA group · Healthy men; age not stated
260 mg8 weeks8
Does maternal docosahexaenoic acid supplementation during pregnancy and lactation lower BMI in late infancy?
2007 · BSF plus fish oil DHA · Pregnant women enrolled at 21 weeks' gestation; followed through lactation
200 mg——
Docosahexaenoic acid supplementation increases prefrontal cortex activation during sustained attention in healthy boys: a placebo-controlled, dose-ranging, functional magnetic resonance imaging study
2010 · low-dose DHA · Healthy boys aged 8–10 years
400 mg8 weeks—
The efficacy of omega-3 supplementation for major depression: a randomized controlled trial
2011 · omega-3 supplementation · Adult outpatients experiencing a major depressive episode lasting at least 4 weeks
150 mg8 weeks—
Prenatal docosahexaenoic acid supplementation and infant morbidity: randomized controlled trial
2011 · DHA group · Pregnant women in Mexico; maternal age and health condition not reported
400 mg——
Omega-3 fatty acid supplementation during pregnancy and respiratory symptoms in children
2014 · DHA · Pregnant women aged 18–35 years; infant respiratory symptoms were assessed, with reported effects among infants of atopic mothers
400 mg——
Maternal single nucleotide polymorphisms in the fatty acid desaturase 1 and 2 coding regions modify the impact of prenatal supplementation with DHA on birth weight
2016 · DHA intervention group · Pregnant Mexican women, from weeks 18–22 of gestation through delivery
400 mg——
Prenatal supplementation with DHA improves attention at 5 y of age: a randomized controlled trial
2016 · DHA group · Pregnant Mexican women; offspring assessed at age 5 years
400 mg——
Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function
2018 · 0.5 g DHA group · Infertile men; age and sex details beyond male participants are not reported
500 mg90 days—
Effects of coadministration of DHA and vitamin E on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial
2020 · DP group · Men aged 20–45 with idiopathic asthenozoospermia and normal endocrine function
465 mg12 weeks—
Docosahexaenoic Acid Supplementation During Pregnancy and Lactation and Infant Morbidity: Findings from DHANI Trial
2025 · DHA group · Healthy pregnant women aged 18–35 years, from 20 weeks’ gestation or earlier through 6 months postpartum
400 mg——
Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis
2026 · fish-oil group · Adults receiving maintenance hemodialysis
800 mg1278 days610
Early and late preterm birth rates in participants adherent to randomly assigned high dose docosahexaenoic acid (DHA) supplementation in pregnancy
2023 · 1000 mg DHA group · Pregnant adults aged 18 or older, enrolled at 12–20 weeks’ gestation
800 mg—576
Higher-Dose DHA Supplementation Modulates Immune Responses in Pregnancy and Is Associated with Decreased Preterm Birth
2021 · 1000 mg group · Pregnant women; age and sex beyond pregnancy not specified
800 mg—465
Fish consumption, erythrocyte fatty acids, and preterm birth
2011 · omega-3 supplementation · Pregnant women with a history of at least one previous spontaneous singleton preterm birth
800 mg146 days434
Effect of n-3 long chain polyunsaturated fatty acid supplementation in pregnancy on infants' allergies in first year of life: randomised controlled trial
2012 · n-3 LCPUFA group · Pregnant women from Adelaide whose unborn baby had a mother, father, or sibling with a history of medically diagnosed allergic disease
800 mg—368
n-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes
2011 · EPA-DHA · Adults aged 60–80 with diabetes and a previous myocardial infarction
149 mg1217 days262
CFH Y402H and ARMS2 A69S Polymorphisms and Oral Supplementation with Docosahexaenoic Acid in Neovascular Age-Related Macular Degeneration Patients: The NAT2 Study
2015 · DHA group · Adults aged 55–85 with early AMD in the study eye and neovascular AMD in the fellow eye
840 mg3 years127
Prevention of postcoronary angioplasty restenosis by omega-3 fatty acids: main results of the Esapent for Prevention of Restenosis ITalian Study (ESPRIT)
2002 · omega-3 FA group · Patients undergoing balloon-only percutaneous transluminal coronary angioplasty (PTCA)
2.1 g240 days125
Effect of Enteral Lipid Supplement on Severe Retinopathy of Prematurity: A Randomized Clinical Trial
2021 · AA:DHA group · Extremely preterm infants born before 28 weeks’ gestational age
50 mg/kg92 days101
Platelet characteristics in extremely preterm infants after fatty acid supplementation: a randomized controlled trial
2025 · AA/DHA supplement · Extremely preterm infants born before 28 weeks’ gestational age
50 mg/kg—84
Allergic disease in infants up to 2 years of age in relation to plasma omega-3 fatty acids and maternal fish oil supplementation in pregnancy and lactation
2011 · ω-3-supplemented group · Pregnant women at risk of having an allergic infant, starting in the 25th gestational week and continuing through breastfeeding
1.1 g—54
Fish oil supplementation in pregnancy and lactation may decrease the risk of infant allergy
2009 · omega-3 group · Pregnant and breastfeeding women with an allergy themselves or a husband or previous child with allergies
1.1 g—52
Change in Blood and Benign Breast Biomarkers in Women Undergoing a Weight-Loss Intervention Randomized to High-Dose ω-3 Fatty Acids versus Placebo
2021 · ω-3-FA · Peri- and postmenopausal women younger than 70 with BMI ≥28 and increased breast-cancer risk
1.05 g1 year23
The N-3 polyunsaturated fatty acids supplementation to prevent depression recurrence in patients with late-life depression: A 52-week double-blind, placebo-controlled trial
2025 · n-3 PUFAs group · Patients with late-life depression who were euthymic at enrollment; ages and sex not reported
1 g52 weeks19
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial
2013 · DHA + EPA group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye
350 mg5 years—
Randomized clinical trial of perioperative omega-3 fatty acid supplements in elective colorectal cancer surgery
2014 · n-3 FA-enriched oral nutritional supplement group · Adults with colorectal cancer referred for elective colorectal cancer surgery; ages 41–89 years, women and men
1 g2 weeks—
Clinical Efficacy and Biological Regulations of ω-3 PUFA-Derived Endocannabinoids in Major Depressive Disorder
2019 · EPA + DHA group · Adults with major depressive disorder
700 mg12 weeks—
Maternal fish oil and/or probiotics intervention: Allergic diseases in children up to two years old
2023 · fish oil + placebo · Women in early pregnancy
1.9 g——
Enteral supplementation with arachidonic and docosahexaenoic acid and pulmonary outcome in extremely preterm infants
2024 · AA and DHA supplementation · Extremely preterm infants
50 mg/kg——
Docosahexaenoic acid supplementation and time at achievement of gross motor milestones in healthy infants: a randomized, prospective, double-blind, placebo-controlled trial
2009 · DHA · Healthy neonates followed throughout the first year of life
20 mg1 year580
Neurodevelopmental outcomes at 7 years' corrected age in preterm infants who were fed high-dose docosahexaenoic acid to term equivalent: a follow-up of a randomised controlled trial
2015 · standard-DHA diet · Infants born before 33 weeks’ gestation
20 mg/kg—313
Neurodevelopmental outcomes at 7 years' corrected age in preterm infants who were fed high-dose docosahexaenoic acid to term equivalent: a follow-up of a randomised controlled trial
2015 · high-DHA diet · Infants born before 33 weeks’ gestation
50 mg/kg—291
Effect of Maternal Docosahexaenoic Acid Supplementation on Very Preterm Infant Growth: Secondary Outcome of a Randomized Clinical Trial
2022 · DHA group · Lactating mothers who delivered before 29 weeks’ gestation; their breastfed very preterm infants were assessed for growth.
1.2 g—273
Docosahexaenoic acid for reading, cognition and behavior in children aged 7-9 years: a randomized, controlled trial (the DOLAB Study)
2012 · Active · Healthy children, mainly aged 7–9 years, attending mainstream schools and selected for below-average reading performance
600 mg16 weeks180
Fatty acids and sleep in UK children: subjective and pilot objective sleep results from the DOLAB study--a randomized controlled trial
2014 · Active treatment · Healthy children aged approximately 6–10 years who were underperforming in reading; not selected for sleep problems
600 mg16 weeks180
Possible effect of DHA intake on body weight reduction and lipid metabolism in obese children
2011 · DHA and EPA intake · Obese children aged 8–12 years
300 mg3 weeks120
DHA supplementation improves cognitive function via enhancing Aβ-mediated autophagy in Chinese elderly with mild cognitive impairment: a randomised placebo-controlled trial
2018 · intervention (DHA) · Elderly Chinese adults with mild cognitive impairment
2 g2 years120
Effects of DHA Supplementation on Hippocampal Volume and Cognitive Function in Older Adults with Mild Cognitive Impairment: A 12-Month Randomized, Double-Blind, Placebo-Controlled Trial
2017 · DHA group · Adults aged 65 years and over with mild cognitive impairment
2 g1 year110
Growth patterns in infants born to women with pregestational overweight/obesity supplemented with docosahexaenoic acid during pregnancy
2024 · PGO-800 group · Pregnant women with pregestational overweight or obesity; age and sex beyond pregnancy not specified
800 mg—88
The effect of fish oil on physical aggression in schoolchildren--a randomized, double-blind, placebo-controlled trial
2005 · fish oil group · Japanese schoolchildren aged 9–12 years, girls and boys
514 mg90 days83
Cognitive Benefits of Folic Acid, Docosahexaenoic Acid, and a Combination of Both Nutrients in Mild Cognitive Impairment: Possible Alterations through Mitochondrial Function and DNA Damage
2024 · DHA · Adults aged 60 years and older with mild cognitive impairment
800 mg1 year70
Supplementation of medium-chain triglycerides combined with docosahexaenoic acid improves cognitive function in Chinese older adults with mild cognitive impairment: A randomized double-blind, placebo-controlled trial
2025 · DHA group · Chinese older adults with mild cognitive impairment
800 mg1 year70
Dietary supplementation with docosahexaenoic acid (DHA) improves seminal antioxidant status and decreases sperm DNA fragmentation
2016 · DHA group · Men who were study subjects; age and condition not specified
1.5 g10 weeks42
The Mothers, Omega-3, and Mental Health Study: a double-blind, randomized controlled trial
2013 · EPA-rich fish oil supplementation · Pregnant women aged 18 years or older, at 12–20 weeks’ gestation and at increased risk for depression, without current major depressive disorder
274 mg—39
Low-dose docosahexaenoic acid lowers diastolic blood pressure in middle-aged men and women
2007 · DHA treatment · Healthy men and women aged 40–65 years
700 mg90 days38
Docosahexaenoic acid in the treatment of rheumatoid arthritis: A double-blind, placebo-controlled, randomized cross-over study with microalgae vs. sunflower oil
2018 · microalgae oil (DHA) · Patients with defined rheumatoid arthritis
2.1 g10 weeks38
Effects of docosahexaenoic acid supplementation during pregnancy on fetal heart rate and variability: a randomized clinical trial
2013 · DHA group · Pregnant women aged 16–35.9 years with singleton pregnancies, enrolled between 12 and 20 weeks of gestation; serious maternal or fetal health conditions were excluded.
600 mg—35
An Exploratory Analysis of Changes in Mental Wellbeing Following Curcumin and Fish Oil Supplementation in Middle-Aged and Older Adults
2020 · FO group · Adults aged 50–80 years who were overweight or obese, sedentary, and without current major depression
400 mg16 weeks31
Does antenatal supplementation with omega-3 affect child development and behavior during the first six months of life? A randomized double-blind placebo-controlled trial
2023 · omega-3 · Low-risk pregnant women recruited at 22–24 weeks of gestation
1.44 g—30
Docosahexaenoic Acid Slows Visual Field Progression in X-Linked Retinitis Pigmentosa: Ancillary Outcomes of the DHAX Trial
2015 · DHA group · Male participants aged 7–31 years with X-linked retinitis pigmentosa
30 mg/kg4 years29
Effect of a Novel Omega-3 and Omega-6 Fatty Acid Supplement on Dry Eye Disease: A 3-month Randomized Controlled Trial
2022 · treatment supplement · Participants with moderate to severe dry eye disease
300 mg90 days24
A randomised controlled trial of vitamin D and omega-3 long chain polyunsaturated fatty acids in the treatment of irritability and hyperactivity among children with autism spectrum disorder
2019 · OM · Children aged 2.5–8 years with autism spectrum disorder
722 mg1 year23
Docosahexaenoic acid (DHA) supplementation in atopic eczema: a randomized, double-blind, controlled trial
2008 · DHA · Adults aged 18–40 with atopic eczema
5.4 g8 weeks21
Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: results from the EARLY study
2004 · DHA supplementation · Children aged 9–19 years with familial hypercholesterolemia or the phenotype of familial combined hyperlipidemia
1.2 g6 weeks20
Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women
2008 · DHA · Women aged 60–80 years without stated cognitive impairment
800 mg120 days14
A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder
2008 · Group A · Adult outpatients with major depressive disorder; mean age 42 years, 46% women
1 g12 weeks14
The Effect of DHA Supplementation on Cognition in Patients with Bipolar Disorder: An Exploratory Randomized Control Trial
2020 · BD patients with Omega 3 · Adults aged 18–65 with euthymic bipolar disorder type I or II
1.25 g12 weeks13
A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder
2008 · Group B · Adult outpatients with major depressive disorder; mean age 42 years, 46% women
2 g12 weeks11
Omega-3 polyunsaturated fatty acids protect against inflammation through production of LOX and CYP450 lipid mediators: relevance for major depression and for human hippocampal neurogenesis
2021 · DHA · Adults with major depressive disorder meeting DSM-IV criteria and baseline 21-item Hamilton Rating Scale for Depression scores of at least 18; sex and age range not reported
1.4 g12 weeks11
Impact of 1-Year Supplementation with High-Rich Docosahexaenoic Acid (DHA) on Clinical Variables and Inflammatory Biomarkers in Pediatric Cystic Fibrosis: A Randomized Double-Blind Controlled Trial
2024 · DHA group · Children aged 6–18 years with cystic fibrosis
50 mg/kg1 year11
A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder
2008 · Group C · Adult outpatients with major depressive disorder; mean age 42 years, 46% women
4 g12 weeks10
Docosahexaenoic acid is a beneficial replacement treatment for spinocerebellar ataxia 38
2017 · DHA treatment, open-label phase · Adults with spinocerebellar ataxia type 38 due to the p.Gly230Val mutation; ages 35–73 years; both sexes
600 mg40 weeks10
The Effect of DHA Supplementation on Cognition in Patients with Bipolar Disorder: An Exploratory Randomized Control Trial
2020 · HCs with Omega 3 · Healthy adults aged 18–65 without DSM-IV Axis I disorders
1.25 g12 weeks7
Long-Chain Omega-3 Fatty Acid Supplementation and Exercise-Induced Muscle Damage: EPA or DHA?
2024 · DHA · Males; age and health status not reported
4 g52 days7
Docosahexaenoic acid is a beneficial replacement treatment for spinocerebellar ataxia 38
2017 · DHA group, randomized double-blind phase · Adults with spinocerebellar ataxia type 38 due to the p.Gly230Val mutation; ages 35–73 years; both sexes
600 mg16 weeks5
Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men
2000 · DHA · Overweight, mildly hyperlipidemic men
4 g6 weeks—
Docosahexaenoic acid supplementation increases prefrontal cortex activation during sustained attention in healthy boys: a placebo-controlled, dose-ranging, functional magnetic resonance imaging study
2010 · high-dose DHA · Healthy boys aged 8–10 years
1.2 g8 weeks—
Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline
2010 · DHA · Healthy adults aged 55 and older with age-related cognitive decline
900 mg24 weeks—
Eicosapentaenoic acid versus docosahexaenoic acid in mild-to-moderate depression: a randomized, double-blind, placebo-controlled trial
2013 · DHA group · Adults with mild-to-moderate depression receiving maintenance medication
1 g12 weeks—
DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial
2013 · DHA group · Healthy adults aged 18–45 years, nonsmoking and with low DHA intake
1.16 g26 weeks—
Docosahexaenoic Acid and Periodontitis in Adults: A Randomized Controlled Trial
2014 · DHA group · Adults with moderate periodontitis
2 g90 days—
Beneficial effects of dietary docosahexaenoic acid intervention on cognitive function and mental health of the oldest elderly in Japanese care facilities and nursing homes
2017 · active group · Elderly care-facility and nursing-home residents, mean age 88.5 years, with cognitive impairment such as dementia
1.72 g1 year—
Prenatal DHA supplementation and infant attention
2016 · Supplemented group · Pregnant women; maternal age and health condition are not specified
600 mg——
Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function
2018 · 1 g DHA group · Infertile men; age and sex details beyond male participants are not reported
1 g90 days—
Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function
2018 · 2 g DHA group · Infertile men; age and sex details beyond male participants are not reported
2 g90 days—
[Docosahexaenoic acid in the treatment of idiopathic male infertility]
2019 · active treatment group · Infertile men with idiopathic male infertility
1.05 g90 days—
Effect of folic acid combined with docosahexaenoic acid intervention on mild cognitive impairment in elderly: a randomized double-blind, placebo-controlled trial
2021 · DHA · Elderly people with mild cognitive impairment (MCI); age range and sex not specified
800 mg26 weeks—
Effects of Folic Acid Combined with DHA Supplementation on Cognitive Function and Amyloid-β-Related Biomarkers in Older Adults with Mild Cognitive Impairment by a Randomized, Double Blind, Placebo-Controlled Trial
2021 · DHA · Adults aged over 60 years with mild cognitive impairment
800 mg26 weeks—
DHA Supplementation During Pregnancy Enhances Maternal Vagally Mediated Cardiac Autonomic Control in Humans
2023 · 800 mg/d DHA · Pregnant women aged 18 years or older with singleton pregnancies, enrolled at 12–20 weeks of gestation
800 mg——
Effects of Prenatal DHA Dose on Infant Visual Attention
2025 · 800 mg/day DHA group · Pregnant women; maternal age and specific eligibility condition not reported
800 mg——
Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans
1998 · DHA group · Healthy, nonsmoking men aged 36–56 years
4 g——
Cow's milk-based beverage consumption in 1- to 4-year-olds and allergic manifestations: an RCT
2016 · CMBB · Children aged 1 to 4 years attending daycare in Brazil; generally healthy, without a stated diagnosed condition
75 mg28 weeks125
The effect of prenatal docosahexaenoic acid supplementation on infant outcomes in African American women living in low-income environments: A randomized, controlled trial
2016 · Active supplement (groups B and C; identical doses) · African American pregnant women aged 20–30 living in low-income environments, with sea fish consumption below 2 servings per week
450 mg—43
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial
2013 · lutein + zeaxanthin and DHA + EPA group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye
350 mg5 years—
Maternal fish oil and/or probiotics intervention: Allergic diseases in children up to two years old
2023 · fish oil + probiotics · Women in early pregnancy
1.9 g——
An Exploratory Analysis of Changes in Mental Wellbeing Following Curcumin and Fish Oil Supplementation in Middle-Aged and Older Adults
2020 · FO + CUR group · Adults aged 50–80 years who were overweight or obese, sedentary, and without current major depression
400 mg16 weeks30
The Cost-Effectiveness of Three Prevention Strategies in Alzheimer's Disease: Results from the Multidomain Alzheimer Preventive Trial (MAPT)
2021 · Omega 3 Polyunsaturated Fatty Acids · Community-dwelling adults aged 70 years and older with a spontaneous memory complaint, limitation in one instrumental activity of daily living, or slow gait
400 mg3 years381
The Cost-Effectiveness of Three Prevention Strategies in Alzheimer's Disease: Results from the Multidomain Alzheimer Preventive Trial (MAPT)
2021 · Combined intervention · Community-dwelling adults aged 70 years and older with a spontaneous memory complaint, limitation in one instrumental activity of daily living, or slow gait
400 mg3 years374
Prenatal Fish Oil Supplementation and Allergy: 6-Year Follow-up of a Randomized Controlled Trial
2016 · n-3 LCPUFA-rich fish oil capsules · Pregnant women with a family history of allergic disease
800 mg—367
The Influence of Prenatal DHA Supplementation on Individual Domains of Behavioral Functioning in School-Aged Children: Follow-Up of a Randomized Controlled Trial
2021 · DHA-rich fish oil · Pregnant women with singleton pregnancies enrolled before 21 weeks’ gestation; no specific diagnosed condition stated
800 mg—351
Effect of Omega-3 on HLA-DR Expression by Conjunctival Cells and Tear Cytokine Concentrations in the Dry Eye Assessment and Management Study
2022 · active supplement group (ω3) · Adults with moderate to severe dry eye disease
1 g1 year349
Oral omega-3 fatty acids treatment in computer vision syndrome related dry eye
2015 · O3FA group · Symptomatic computer users using computers more than 3 hours per day for at least 1 year; sex and age not specified; computer vision syndrome-related dry eye
240 mg90 days220
Docosahexaenoic Acid and Arachidonic Acid Supplementation and Sleep in Toddlers Born Preterm: Secondary Analysis of a Randomized Clinical Trial
2019 · DHA+AA supplementation · Children aged 10 to 16 months at enrollment, born before 35 weeks' gestation
200 mg180 days193
Docosahexaenoic acid supplementation, vascular function and risk factors for cardiovascular disease: a randomized controlled trial in young adults
2013 · DHA supplemented group · Healthy adults aged 18–37 years, men and women, without chronic disease likely to affect endothelial function
1.6 g120 days162
Fatty Acid Supplementation and Socioemotional Outcomes: Secondary Analysis of a Randomized Trial
2020 · DHA + AA · Children aged 10 to 16 months at enrollment, born at less than 35 weeks' gestation
200 mg180 days161
Effects of Varied Omega-3 Fatty Acid Supplementation on Postpartum Mental Health and the Association between Prenatal Erythrocyte Omega-3 Fatty Acid Levels and Postpartum Mental Health
2023 · fish oil group · Healthy primiparous pregnant women aged 19–45 years
400 mg12 weeks124
The effects of docosahexaenoic acid-rich fish oil on behavior, school attendance rate and malaria infection in school children--a double-blind, randomized, placebo-controlled trial in Lampung, Indonesia
2008 · DHA group · Fourth- to sixth-grade school children, mostly aged 9–12 years, in Lampung, Indonesia
650 mg90 days116
Supplementation with oil rich in eicosapentaenoic acid, but not in docosahexaenoic acid, improves global cognitive function in healthy, young adults: results from randomized controlled trials
2021 · DHA-rich oil · Healthy adults aged 25–49 who habitually consumed oily fish less than once per week and reported no habitual dietary supplement use
900 mg26 weeks113
Supplementation with oil rich in eicosapentaenoic acid, but not in docosahexaenoic acid, improves global cognitive function in healthy, young adults: results from randomized controlled trials
2021 · EPA-rich oil · Healthy adults aged 25–49 who habitually consumed oily fish less than once per week and reported no habitual dietary supplement use
360 mg26 weeks112
Fish oil n-3 polyunsaturated fatty acids selectively affect plasma cytokines and decrease illness in Thai schoolchildren: a randomized, double-blind, placebo-controlled intervention trial
2009 · fish oil · Thai schoolchildren aged 9 to 12 years
1 g26 weeks94
Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study
2009 · Omega-3/Omega-3 group · Adults aged about 73 years with mild to moderate Alzheimer's disease
1.7 g1 year89
Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer's Disease: The OmegAD Study
2019 · omega-3 fatty acid supplementation · Community-based patients with mild to moderate Alzheimer's disease, MMSE ≥15; 88 participants received supplementation
1.7 g26 weeks88
Long-chain PUFA supplementation in rural African infants: a randomized controlled trial of effects on gut integrity, growth, and cognitive development
2013 · fish-oil group · Gambian infants, approximately 3–9 months old, living in rural West Kiang; no specific diagnosed condition required
200 mg26 weeks87
Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study
2009 · Placebo/Omega-3 group · Adults aged about 73 years with mild to moderate Alzheimer's disease
1.7 g26 weeks85
Evaluation of the Retinopathy of Prematurity Activity Scale (ROP-ActS) in a randomised controlled trial aiming for prevention of severe ROP: a substudy of the Mega Donna Mega trial
2022 · AA:DHA · Infants born before 28 weeks of gestational age
50 mg/kg—84
Fish Oil And/Or Probiotics Intervention in Overweight/Obese Pregnant Women and Overweight Risk in 24-Month-Old Children
2023 · Fish oil + placebo · Pregnant women with overweight or obesity, enrolled before 18 gestational weeks; no chronic diseases stated
3.8 g—82
Fish Oil And/Or Probiotics Intervention in Overweight/Obese Pregnant Women and Overweight Risk in 24-Month-Old Children
2023 · Probiotics + fish oil · Pregnant women with overweight or obesity, enrolled before 18 gestational weeks; no chronic diseases stated
3.8 g—82
The effect of perinatal fish oil supplementation on neurodevelopment and growth of infants: a randomized controlled trial
2018 · fish oil supplementation group · Pregnant women aged 18–35 years
120 mg—75
Cognitive Benefits of Folic Acid, Docosahexaenoic Acid, and a Combination of Both Nutrients in Mild Cognitive Impairment: Possible Alterations through Mitochondrial Function and DNA Damage
2024 · FA + DHA · Adults aged 60 years and older with mild cognitive impairment
800 mg1 year70
Supplementation of medium-chain triglycerides combined with docosahexaenoic acid improves cognitive function in Chinese older adults with mild cognitive impairment: A randomized double-blind, placebo-controlled trial
2025 · MCT + DHA group · Chinese older adults with mild cognitive impairment
800 mg1 year70
Developmental Outcomes at 24 Months of Age in Toddlers Supplemented with Arachidonic Acid and Docosahexaenoic Acid: Results of a Double Blind Randomized, Controlled Trial
2017 · DHA/ARA supplement group · Healthy term-born toddlers enrolled at 12–14 months of age
200 mg1 year68
Re-Esterified Triglyceride ω-3 Fatty Acids in Dry Eye Disease With Meibomian Gland Dysfunction: A Randomized Clinical Trial
2024 · ω-3 group · Korean adults aged 20–75 with dry eye disease and concurrent meibomian gland dysfunction; both sexes
560 mg12 weeks66
Effects of Marine n-3 Polyunsaturated Fatty Acids on Heart Rate Variability and Heart Rate in Patients on Chronic Dialysis: A Randomized Controlled Trial
2018 · n-3 PUFA group · Adults over 18 years receiving chronic dialysis for more than 3 months
1 g90 days56
Long-chain Polyunsaturated Fatty Acid Supplementation Improves Mood in Elderly Japanese Men
2017 · LCPUFA group · Japanese men aged 55–64 years
300 mg4 weeks51
The n-3 Polyunsaturated Fatty Acids Supplementation Improved the Cognitive Function in the Chinese Elderly with Mild Cognitive Impairment: A Double-Blind Randomized Controlled Trial
2017 · n-3 PUFA · Chinese adults aged 60 years or older with mild cognitive impairment
480 mg26 weeks44
Foods, nutrients or whole diets: effects of targeting fish and LCn3PUFA consumption in a 12mo weight loss trial
2013 · Fish + S · Adults aged 18–60 years with overweight or obesity (BMI 25–37 kg/m²), otherwise healthy
210 mg1 year40
The Mothers, Omega-3, and Mental Health Study: a double-blind, randomized controlled trial
2013 · DHA-rich fish oil supplementation · Pregnant women aged 18 years or older, at 12–20 weeks’ gestation and at increased risk for depression, without current major depressive disorder
900 mg—38
Long-Chain Polyunsaturated Fatty Acids, Homocysteine at Birth and Fatty Acid Desaturase Gene Cluster Polymorphisms are Associated with Children's Processing Speed up to Age 9 Years
2020 · FO · Healthy pregnant women; offspring were assessed at 7.5 and 9 years
500 mg—38
Long-Chain Polyunsaturated Fatty Acids, Homocysteine at Birth and Fatty Acid Desaturase Gene Cluster Polymorphisms are Associated with Children's Processing Speed up to Age 9 Years
2020 · FO + 5-MTHF · Healthy pregnant women; offspring were assessed at 7.5 and 9 years
500 mg—36
Cognitive assessment of children at age 2(1/2) years after maternal fish oil supplementation in pregnancy: a randomised controlled trial
2008 · fish oil group · Pregnant women receiving supplementation from 20 weeks’ gestation until delivery; their children were assessed at age 2.5 years
2.2 g—33
Effects of ω-3 PUFAs supplementation on myocardial function and oxidative stress markers in typical Rett syndrome
2014 · ω-3 PUFAs arm · Girls aged 12.7 ± 9.1 years on average with typical Rett syndrome and a demonstrated MeCP2 mutation
71.9 mg/kg1 year33
Effect of Docosahexaenoic Acid and Eicosapentaenoic Acid Supplementation on Sleep Quality in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Trial
2022 · DHA/EPA supplementation group · Healthy Japanese adults aged 45 years or older with poor sleep quality; male and female
576 mg12 weeks33
The Efficacy of Omega-3 Fatty Acids as the Monotherapy for Depression: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
2024 · n-3 PUFAs group · Adults aged 18–65 with major depressive disorder and HRSD-21 score >18
1.1 g12 weeks30
Differential Effects of DHA- and EPA-Rich Oils on Sleep in Healthy Young Adults: A Randomized Controlled Trial
2021 · DHA-rich oil group · Healthy adults aged 25–49 years, male and female, consuming oily fish less than once per week
900 mg26 weeks29
Effects of omega-3 fatty acid supplementation on cigarette craving and oxidative stress index in heavy-smoker males: A double-blind, randomized, placebo-controlled clinical trial
2018 · fish-oil-derived omega-3 fatty acid supplements · heavy-smoker males who smoked at least 20 cigarettes per day
600 mg90 days27
Differential Effects of DHA- and EPA-Rich Oils on Sleep in Healthy Young Adults: A Randomized Controlled Trial
2021 · EPA-rich oil group · Healthy adults aged 25–49 years, male and female, consuming oily fish less than once per week
360 mg26 weeks27
Fish oil supplementation alters emotion-generated corticolimbic functional connectivity in depressed adolescents at high-risk for bipolar I disorder: A 12-week placebo-controlled fMRI trial
2022 · FO group · Youth aged 9–21 years with major depressive disorder or Depressive Disorder NOS and a biological parent with bipolar I disorder
780 mg12 weeks27
Cognitive response to fish oil, blueberry, and combined supplementation in older adults with subjective cognitive impairment
2018 · FO + BB · Men and women aged 62–80 with mild self-perceived cognitive decline and no objective cognitive impairment
800 mg24 weeks26
Longitudinal investigation of the relationship between omega-3 polyunsaturated fatty acids and neuropsychological functioning in recent-onset psychosis: A randomized clinical trial
2021 · Risperidone + fish oil (FO) · Patients aged 15–40 with recent-onset psychosis, including schizophrenia-spectrum and bipolar disorder with psychosis
400 mg16 weeks25
Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial
2007 · n-3 EFA group · Patients presenting after recurrent self-harm
900 mg12 weeks22
Cognitive response to fish oil, blueberry, and combined supplementation in older adults with subjective cognitive impairment
2018 · FO · Men and women aged 62–80 with mild self-perceived cognitive decline and no objective cognitive impairment
800 mg24 weeks21
Effects of combining exercise with long-chain polyunsaturated fatty acid supplementation on cognitive function in the elderly: a randomised controlled trial
2020 · Ex + LCPUFA · Japanese adults aged 60–79 who were not exercising regularly, had age-related cognitive-decline complaints and lower memory scores, and did not have dementia; exercise arm participants had low skeletal muscle mass in the reported subgroup analysis
300 mg24 weeks21
Emotion-Related Network Reorganization Following Fish Oil Supplementation in Depressed Bipolar Offspring: An fMRI Graph-Based Connectome Analysis
2021 · Fish oil · Patients aged 9–21 with a depressive disorder and a biological parent with bipolar I disorder
780 mg12 weeks21
Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents
1996 · First group: fish oil followed by placebo · Adolescent girls with dysmenorrhea
720 mg60 days21
Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents
1996 · Second group: placebo followed by fish oil · Adolescent girls with dysmenorrhea
720 mg60 days21
Effects of dietary omega-3 fatty acid supplementation on endothelium-dependent vasodilation in patients with chronic heart failure
2006 · omega-3 fatty acid · Adults aged 65 years or older with grade II or III chronic heart failure
1.2 g6 weeks20
Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder
2012 · citalopram + omega-3 treatment group · Adults aged 18–65 with major depressive disorder and HAM-D score greater than 17
200 mg8 weeks20
Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects
1990 · low-dose fish oil group · Patients with active rheumatoid arthritis; age and sex not specified
18 mg/kg24 weeks20
Omega-3 polyunsaturated fatty acids-enriched hen eggs consumption enhances microvascular reactivity in young healthy individuals
2018 · OMEGA-3 group · Young healthy individuals; age range and sex not specified
252 mg3 weeks20
Omega-3 polyunsaturated fatty acids (n-3 PUFAs), somatic and fatigue symptoms in cardiovascular diseases comorbid major depressive disorder (MDD): A randomized controlled trial
2023 · n-3 PUFAs group · Adults with cardiovascular diseases comorbid with major depressive disorder; mean age 60 ± 9 years, 58% male
1 g12 weeks20
Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial
2012 · DHA-rich supplement · Adults older than 65 years with mild cognitive impairment
1.55 g26 weeks18
The effects of EPA and DHA enriched fish oil on nutritional and immunological markers of treatment naïve breast cancer patients: a randomized double-blind controlled trial
2017 · Fish oil group (FG) · Women aged 18–70 with newly diagnosed, treatment-naïve breast cancer before surgery
780 mg30 days18
Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial
2012 · EPA-rich supplement · Adults older than 65 years with mild cognitive impairment
160 mg26 weeks17
Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects
1990 · high-dose fish oil group · Patients with active rheumatoid arthritis; age and sex not specified
36 mg/kg24 weeks17
Effects of dietary supplementation with fish oil on dry eye syndrome subjects: randomized controlled trial
2013 · fish oil group · People with dry eye syndrome
540 mg12 weeks15
Fish Oil Supplementation Increases Event-Related Posterior Cingulate Activation in Older Adults with Subjective Memory Impairment
2016 · Fish oil group · Older adults with subjective memory impairment, without mild cognitive impairment or dementia; age range and sex distribution not specified
800 mg24 weeks15
A randomised controlled trial of vitamin D and omega-3 long chain polyunsaturated fatty acids in the treatment of irritability and hyperactivity among children with autism spectrum disorder
2019 · VIDOM · Children aged 2.5–8 years with autism spectrum disorder
722 mg1 year15
Effects of omega-3 supplementation as an adjunct to non-surgical periodontal therapy on periodontal parameters in periodontitis patients: a randomized clinical trial
2022 · Intervention group · Adults aged 30–70 with stage II–IV, grade B periodontitis
120 mg90 days15
Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women
2008 · Combination of DHA and lutein · Women aged 60–80 years without stated cognitive impairment
800 mg120 days14
Long-chain n-3 polyunsaturated fatty acids decrease feelings of anger in substance abusers
2008 · PUFA group · Men admitted to substance abuse clinics, without the listed major physical illnesses or excluded psychiatric disorders
500 mg90 days13
Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators
2023 · EPA 1 g/d · Adults with non-psychotic major depressive disorder, BMI >25 kg/m², and low-grade chronic inflammation (hs-CRP ≥3 µg/mL)
1.22 g12 weeks13
Omega-3 fatty acid supplementation enhances stroke volume and cardiac output during dynamic exercise
2008 · DHA + EPA · Healthy adult men and women; ages not reported
2 g6 weeks12
Eicosapentaenoic and docosahexaenoic acids-rich fish oil supplementation attenuates strength loss and limited joint range of motion after eccentric contractions: a randomized, double-blind, placebo-controlled, parallel-group trial
2016 · EPA group · Healthy Japanese men, mean age 19.4 years; no stated diagnosed condition
260 mg62 days12
Resting metabolic rate and skeletal muscle SERCA and Na(+) /K(+) ATPase activities are not affected by fish oil supplementation in healthy older adults
2020 · Fish oil group · Healthy physically active men and women aged 60–75 years
1 g12 weeks12
4-week eicosapentaenoic acid-rich fish oil supplementation partially protects muscular damage following eccentric contractions
2021 · EPA and DHA group · Healthy recreationally untrained men; age range not stated
260 mg33 days11
Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators
2023 · EPA 2 g/d · Adults with non-psychotic major depressive disorder, BMI >25 kg/m², and low-grade chronic inflammation (hs-CRP ≥3 µg/mL)
1.22 g12 weeks11
Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators
2023 · EPA 4 g/d · Adults with non-psychotic major depressive disorder, BMI >25 kg/m², and low-grade chronic inflammation (hs-CRP ≥3 µg/mL)
1.22 g12 weeks11
Effect of eicosapentaenoic acids-rich fish oil supplementation on motor nerve function after eccentric contractions
2017 · EPA group · Healthy men, mean age 20.7 years; untrained and without a stated diagnosed condition
260 mg62 days10
Omega-3 fatty acids enhance the beneficial effect of BCAA supplementation on muscle function following eccentric contractions
2022 · BCAA+FO group · Healthy, untrained men aged 19–20 years
260 mg61 days10
The effect of fish oil supplementation on resistance training-induced adaptations
2023 · Fish Oil (FOS) · Adults aged 18–40, men and women, recreationally resistance-trained, without stated chronic disease
1.58 g10 weeks10
Distal proctocolitis and n-3 polyunsaturated fatty acids (n-3 PUFAs): the mucosal effect in situ
2000 · fish oil extract · Patients with distal proctocolitis; age and sex not reported
2.4 g26 weeks9
Distal procto-colitis, natural cytotoxicity, and essential fatty acids
1998 · fish oil extract · Patients with distal procto-colitis; age and sex not reported
2.4 g26 weeks9
Omega-3 supplementation is neuroprotective to corneal nerves in dry eye disease: a pilot study
2017 · ω-3 EFA supplements · Adults with moderate dry eye disease; age and sex not reported
500 mg90 days8
Supplementation of eicosapentaenoic acid-rich fish oil attenuates muscle stiffness after eccentric contractions of human elbow flexors
2019 · EPA group · Healthy men, approximately 20–22 years old, without resistance training
260 mg62 days8
Long-chain n-3 polyunsaturated fatty acids decrease feelings of anger in substance abusers
2008 · PUFA group, six-month follow-up subset · Men admitted to substance abuse clinics, without the listed major physical illnesses or excluded psychiatric disorders
500 mg90 days6
Fish oil supplementation reduces severity of exercise-induced bronchoconstriction in elite athletes
2003 · n-3 PUFA diet · Elite athletes, including athletes with exercise-induced bronchoconstriction (EIB) and athletes without EIB; age and sex not reported
2.2 g3 weeks5
Dietary omega-3 fatty acid supplementation and naproxen treatment in patients with rheumatoid arthritis
1992 · Group 2 · Patients with active rheumatoid arthritis
2 g16 weeks—
Dietary omega-3 fatty acid supplementation and naproxen treatment in patients with rheumatoid arthritis
1992 · Group 3 · Patients with active rheumatoid arthritis
2 g16 weeks—
Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses
2004 · DHA + A group · Adults aged 18 to 55 years with retinitis pigmentosa; subgroup analyses distinguished prior vitamin A use
1.2 g1461 days—
Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions
2006 · omega-3 fatty acids · White men with a history of myocardial infarction and ejection fractions below 40%
585 mg120 days—
Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study
2007 · omega-3 fatty acids · Children aged 5 to 17 years with autistic disorders accompanied by severe tantrums, aggression, or self-injurious behavior
700 mg6 weeks—
Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial
2006 · omega-3 fatty acid-treated group · Adults with mild to moderate Alzheimer disease, age range 74 ± 9 years; sex not specified
1.7 g26 weeks—
Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial
2006 · placebo group after crossover to omega-3 fatty acid supplementation · Adults with mild to moderate Alzheimer disease, age range 74 ± 9 years; sex not specified
1.7 g26 weeks—
Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers
2008 · PUFA group · Men admitted to substance-abuse outpatient clinics, with polysubstance abuse and suboptimal dietary intake of long-chain n-3 PUFAs
500 mg90 days—
Docosahexaenoic acid-rich fish oil improves heart rate variability and heart rate responses to exercise in overweight adults
2008 · Fish oil, no regular physical activity · Sedentary, overweight adults with risk factors for coronary disease
1.56 g12 weeks—
Docosahexaenoic acid-rich fish oil improves heart rate variability and heart rate responses to exercise in overweight adults
2008 · Fish oil with regular physical activity · Sedentary, overweight adults with risk factors for coronary disease
1.56 g12 weeks—
Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment
2010 · Intervention group · Patients with stage III non-small cell lung cancer undergoing multimodality treatment; age and sex not specified
900 mg5 weeks—
Effects of prenatal fish-oil and 5-methyltetrahydrofolate supplementation on cognitive development of children at 6.5 y of age
2011 · fish-oil group · healthy pregnant women
500 mg——
Effects of prenatal fish-oil and 5-methyltetrahydrofolate supplementation on cognitive development of children at 6.5 y of age
2011 · combined fish-oil and 5-MTHF group · healthy pregnant women
500 mg——
The effect of a 1-year multiple micronutrient or n-3 fatty acid fortified food intervention on morbidity in Indian school children
2012 · High micronutrients + high n-3 fatty acids · Children aged 6–10 years in India
100 mg1 year—
The effect of a 1-year multiple micronutrient or n-3 fatty acid fortified food intervention on morbidity in Indian school children
2012 · Low micronutrients + high n-3 fatty acids · Children aged 6–10 years in India
100 mg1 year—
Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study
2012 · n-3 group · Patients with advanced inoperable non-small-cell lung cancer undergoing chemotherapy
340 mg66 days—
Fish oil supplementation improves neutrophil function during cancer chemotherapy
2012 · FO · Cancer patients receiving chemotherapy after surgical tumor removal, mainly gastrointestinal cancers; age and sex not stated
400 mg8 weeks—
Effects of high-dose fish oil supplementation during early infancy on neurodevelopment and language: a randomised controlled trial
2012 · DHA-enriched fish oil group · Healthy term infants, from birth to 6 months
250 mg26 weeks—
Fish oil supplementation reduces cortisol basal levels and perceived stress: a randomized, placebo-controlled trial in abstinent alcoholics
2013 · fish-oil supplementation · Adult men with alcohol dependence undergoing residential rehabilitation
252 mg3 weeks—
Improvement of major depression is associated with increased erythrocyte DHA
2013 · HiDHA · Adults receiving treatment for major depression
2 g16 weeks—
Effects of fish oil supplementation on learning and behaviour of children from Australian Indigenous remote community schools: a randomised controlled trial
2013 · fish oil capsules · children aged 3–13 years attending Australian Indigenous remote community schools
750 mg40 weeks—
The effect of omega-3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: a randomized, placebo-controlled clinical trial
2014 · omega-3 group · Maintenance hemodialysis patients; age range and sex not reported
360 mg120 days—
Effects of omega-3 fatty acids on tobacco craving in cigarette smokers: A double-blind, randomized, placebo-controlled pilot study
2014 · omega-3 fatty acid supplementation · Regular cigarette smokers
2.04 g30 days—
Effects of omega-3 fatty acids on depression and quality of life in maintenance hemodialysis patients
2014 · omega-3 fatty acids group · Adults with depressive symptoms (BDI score ≥16) receiving maintenance hemodialysis for at least 3 months
720 mg120 days—
Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder
2015 · ADHD Active · Boys aged 8–14 with ADHD
650 mg16 weeks—
Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder
2015 · RG Active · Typically developing boys matched to the ADHD participants for age, hand preference, and BMI
650 mg16 weeks—
Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study
2016 · EPA-enriched mix · Adults aged 18–80 with major depressive disorder
260 mg8 weeks—
Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study
2016 · DHA-enriched mix · Adults aged 18–80 with major depressive disorder
900 mg8 weeks—
Low Doses of Long-chain Polyunsaturated Fatty Acids Affect Cognitive Function in Elderly Japanese Men: A Randomized Controlled Trial
2015 · LCPUFA group · Japanese men aged 55–64 years without dementia
300 mg4 weeks—
Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial
2015 · DHA/EPA · Older adults with intermediate or late age-related macular degeneration; mean age about 73 years, both sexes
350 mg5 years—
Effects of omega-3 polyunsaturated fatty acids on psychophysiological symptoms of post-traumatic stress disorder in accident survivors: A randomized, double-blind, placebo-controlled trial
2017 · omega-3 PUFAs · Japanese accident survivors who began supplementation within 10 days of accidental injury
1.47 g12 weeks—
Change in blood levels of eicosapentaenoic acid and posttraumatic stress symptom: A secondary analysis of data from a placebo-controlled trial of omega3 supplements
2016 · omega3 supplements arm · Participants with severe physical injury; age and sex not reported
1.47 g12 weeks—
Omega-3 supplements reduce self-reported physical aggression in healthy adults
2018 · Omega-3 supplements · Adults aged 18–45 from the general population
638 mg6 weeks—
ω-3 and ω-6 Fatty Acid Supplementation May Reduce Autism Symptoms Based on Parent Report in Preterm Toddlers
2018 · Omega-3-6-9 Junior treatment · Children aged 18–38 months born at 29 weeks’ gestation or earlier, exhibiting early signs of ASD
225 mg90 days—
Omega-3 supplementation effects on body weight and depression among dieter women with co-morbidity of depression and obesity compared with the placebo: A randomized clinical trial
2018 · omega-3 group · Women with depression and overweight or obesity (BMI ≥25) seeking weight reduction
720 mg12 weeks—
Adding omega-3 fatty acids to a protein-based supplement during pre-season training results in reduced muscle soreness and the better maintenance of explosive power in professional Rugby Union players
2018 · FO · Professional Rugby Union players undergoing pre-season training; age and sex not stated
1.1 g5 weeks—
Effects of fish oil and curcumin supplementation on cerebrovascular function in older adults: A randomized controlled trial
2020 · fish oil · Sedentary overweight/obese adults aged 50–80 years
2 g16 weeks—
Effects of fish oil and curcumin supplementation on cerebrovascular function in older adults: A randomized controlled trial
2020 · combination of fish oil and curcumin · Sedentary overweight/obese adults aged 50–80 years
2 g16 weeks—
Effects of coadministration of DHA and vitamin E on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial
2020 · DE group · Men aged 20–45 with idiopathic asthenozoospermia and normal endocrine function
465 mg12 weeks—
Effect of folic acid combined with docosahexaenoic acid intervention on mild cognitive impairment in elderly: a randomized double-blind, placebo-controlled trial
2021 · FA + DHA · Elderly people with mild cognitive impairment (MCI); age range and sex not specified
800 mg26 weeks—
Re-esterified DHA improves ventilatory threshold 2 in competitive amateur cyclists
2020 · DHA · Male amateur cyclists older than 18 years, competing at regional level and training 2–4 sessions per week
975 mg30 days—
Effects of Folic Acid Combined with DHA Supplementation on Cognitive Function and Amyloid-β-Related Biomarkers in Older Adults with Mild Cognitive Impairment by a Randomized, Double Blind, Placebo-Controlled Trial
2021 · folic acid + DHA · Adults aged over 60 years with mild cognitive impairment
800 mg26 weeks—
Effects of DHA-Rich n-3 Fatty Acid Supplementation and/or Resistance Training on Body Composition and Cardiometabolic Biomarkers in Overweight and Obese Post-Menopausal Women
2021 · omega-3 group (n-3) · Women aged 55–70 who were overweight or obese and postmenopausal
1.65 g16 weeks—
Effects of DHA-Rich n-3 Fatty Acid Supplementation and/or Resistance Training on Body Composition and Cardiometabolic Biomarkers in Overweight and Obese Post-Menopausal Women
2021 · omega-3 + resistance training group (n-3+RT) · Women aged 55–70 who were overweight or obese and postmenopausal
1.65 g16 weeks—
Effect of arachidonic and docosahexaenoic acid supplementation on respiratory outcomes and neonatal morbidities in preterm infants
2023 · intervention · Very preterm infants with gestational age less than 29 weeks
50 mg/kg——
Effect of Docosahexaenoic Acid (DHA) Supplementation of Preterm Infants on Growth, Body Composition, and Blood Pressure at 7-Years Corrected Age: Follow-Up of a Randomized Controlled Trial
2023 · high-DHA diet (intervention) · Preterm infants born before 33 weeks gestation and their breastfeeding mothers; enrolled within 5 days of commencing enteral feeds
900 mg——
Effect of arachidonic and docosahexaenoic acid supplementation on quality of growth in preterm infants: A secondary analysis of a randomized controlled trial
2023 · ARA:DHA group · Infants born before 29 weeks of gestation
50 mg/kg——
Omega-3 polyunsaturated fatty acids supplementation improves memory in first-diagnosed, drug-naïve patients with depression: Secondary analysis of data from a randomized controlled trial
2024 · n-3 PUFAs supplementation · Outpatients with first-diagnosed, drug-naïve depression receiving venlafaxine; age and sex not reported
960 mg12 weeks—
Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis--a double-blind placebo controlled study
1993 · Maxepa · Patients with stable mild rheumatoid arthritis requiring NSAID therapy only; age and sex not reported
1.14 g1 year—
High-Dose DHA Has More Profound Effects on LDL-Related Features Than High-Dose EPA: The ComparED Study
2018 · phase 2: DHA · Adults with abdominal obesity and subclinical inflammation at risk of cardiovascular disease; 48 men and 106 women enrolled
2.7 g10 weeks154
Effect of Prenatal Docosahexaenoic Acid Supplementation on Blood Pressure in Children With Overweight Condition or Obesity: A Secondary Analysis of a Randomized Clinical Trial
2019 · DHA group · Pregnant women enrolled before 20 weeks’ gestation; no stated health condition
600 mg—89
LDL cholesterol-raising effect of low-dose docosahexaenoic acid in middle-aged men and women
2004 · DHA treatment · Men and women aged 40–65 years
700 mg90 days38
Docosahexaenoic acid reduces resting blood pressure but increases muscle sympathetic outflow compared with eicosapentaenoic acid in healthy men and women
2019 · DHA · Healthy young men and women
3 g12 weeks28
Ethyl EPA and ethyl DHA cause similar and differential changes in plasma lipid concentrations and lipid metabolism in subjects with low-grade chronic inflammation
2022 · DHA supplementation · Adults aged 50–75 with low-grade chronic inflammation and at least one characteristic of metabolic syndrome; women were postmenopausal
3 g10 weeks21
Sodium transport kinetics, cell membrane lipid composition, neural conduction and metabolic control in type 1 diabetic patients. Changes after a low-dose n-3 fatty acid dietary intervention
1999 · supplemented group · Type 1 diabetic patients
330 mg——
Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans
1999 · purified DHA · overweight, mildly hyperlipidemic men
4 g6 weeks—
Impact of DHA from Algal Oil on the Breast Milk DHA Levels of Lactating Women: A Randomized Controlled Trial in China
2022 · supplement group · Healthy lactating women aged 20–40 years, exclusively breastfeeding, 30–50 days postpartum, with no stated disease
200 mg8 weeks77
Changes in fatty acid levels after consumption of a novel docosahexaenoic supplement from algae: a crossover randomized controlled trial in omnivorous, lacto-ovo vegetarians and vegans
2023 · DHA-supplement · Healthy adults aged 18–45 consuming a vegetarian diet for at least 6 months or an omnivorous diet with low fish intake
250 mg5 weeks51
Supplementation with docosahexaenoic acid in the last trimester of pregnancy: maternal-fetal biochemical findings
2004 · study group (group A) · pregnant women in the last trimester
200 mg—20
Bioequivalence of Docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food
2007 · DHASCO-T capsules, 200 mg DHA/day · Adults; age, sex, and health condition not specified
200 mg4 weeks12
Bioequivalence of Docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food
2007 · DHASCO-S capsules, 200 mg DHA/day · Adults; age, sex, and health condition not specified
200 mg4 weeks12
Docosahexaenoic acid transfer into human milk after dietary supplementation: a randomized clinical trial
2000 · DHA-rich oil group · Lactating women, 4–6 weeks postpartum
200 mg2 weeks5
Human milk arachidonic acid and docosahexaenoic acid contents increase following supplementation during pregnancy and lactation
2009 · DHA · Women supplemented during pregnancy and lactation
220 mg——
Docosahexaenoic acid (DHA) supplementation of orange juice increases plasma phospholipid DHA content of children
2009 · higher dose · Healthy children aged 4–6 and 7–12 years
100 mg6 weeks—
Toddler formula supplemented with docosahexaenoic acid (DHA) improves DHA status and respiratory health in a randomized, double-blind, controlled trial of US children less than 3 years of age
2010 · 130 mg DHA per day · Children aged 18–36 months, with no condition stated
130 mg60 days—
Docosahexaenoic acid supplementation in pregnancy and early lactation: Impacts on breast milk docosahexaenoic acid and Maternal-Infant gut microbiota - A randomized controlled trial
2025 · FC · Chinese pregnant women receiving supplementation during the third trimester
100 mg——
Docosahexaenoic acid supplementation in pregnancy and early lactation: Impacts on breast milk docosahexaenoic acid and Maternal-Infant gut microbiota - A randomized controlled trial
2025 · FF · Chinese pregnant women who continued supplementation through 42 days postpartum
100 mg——
Effect of maternal docosahexaenoic acid (DHA) supplementation on breast milk composition
1996 · 0.2 g DHA/day group · Lactating mothers, randomised on day 5 postpartum
200 mg——
The effects of omega-3 fatty acids on neuropsychological functioning and brain morphology in mid-life adults: a randomized clinical trial
2020 · fish oil group · Adults aged 30–54 years with low dietary EPA and DHA intake and no stated diagnosed condition
400 mg18 weeks134
Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults
2023 · LCPUFAs + LZ group, Trial 2 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23
300 mg12 weeks96
Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients With Coronary Artery Disease: Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial
2016 · n-3 PUFA treatment · Men and women aged 45–80 with stable coronary artery disease participating in cardiac rehabilitation, with or without a depressive episode
600 mg12 weeks46
Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids
2015 · ω-3 PUFA group · People aged 13–25 with ultra-high risk for psychosis
480 mg12 weeks40
Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults
2023 · LCPUFAs + LZ group, Trial 1 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23
300 mg24 weeks40
Omega-3 fatty acid, carotenoid and vitamin E supplementation improves working memory in older adults: A randomised clinical trial
2022 · active group · Cognitively healthy adults aged 65 years and older
430 mg2 years30
Effect of Omega-3 Polyunsaturated Fatty Acid Supplementation on Clinical Outcome of Atopic Dermatitis in Children
2024 · intervention group · Children aged 1–8 years with moderate-to-severe atopic dermatitis
400 mg120 days26
Clinical and microbiological outcomes of subgingival instrumentation supplemented with high-dose omega-3 polyunsaturated fatty acids in periodontal treatment - a randomized clinical trial
2023 · Test group (SRP plus fish oil) · Adults aged 22–70 with generalized stage III or IV periodontitis
1.8 g26 weeks24
The Effects of a 6-Month High Dose Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins Supplementation on Cognitive Function and Functional Capacity in Older Adults with Mild Cognitive Impairment
2020 · omega supplementation group · Adults aged 65 years or older with mild cognitive impairment
4.14 g26 weeks23
Omega-3 fatty acids modify human cortical visual processing--a double-blind, crossover study
2011 · EPA-rich formulation · Healthy adults aged 19–34 years without known neurological or psychiatric conditions
137 mg30 days22
Omega-3 fatty acids modify human cortical visual processing--a double-blind, crossover study
2011 · DHA-rich formulation · Healthy adults aged 19–34 years without known neurological or psychiatric conditions
417 mg30 days22
Benefits of Krill Oil Supplementation During Alternate-Day Fasting in Adults With Overweight and Obesity: A Randomized Trial
2025 · KO group · Healthy adults aged 25–65 with BMI >25 kg/m² and overweight or obesity; 25 women and 16 men enrolled
188 mg12 weeks21
Omega-3 Polyunsaturated Fatty Acids EPA and DHA as an Adjunct to Non-Surgical Treatment of Periodontitis: A Randomized Clinical Trial
2020 · Test group · Adults aged 22–70 with generalized stage III or IV periodontitis
1.8 g90 days20
Neuroaspis PLP10™, a nutritional formula rich in omega-3 and omega-6 fatty acids with antioxidant vitamins including gamma-tocopherol in early Parkinson's disease: A randomized, double-blind, placebo-controlled trial
2021 · Neuroaspis PLP10™ · Patients with Parkinson's disease; age and sex not reported.
4.14 g913 days20
Antioxidant and Anti-Inflammatory Effects of Oral Supplementation with a Highly-Concentrated Docosahexaenoic Acid (DHA) Triglyceride in Patients with Keratoconus: A Randomized Controlled Preliminary Study
2023 · DHA group · Adults aged 18 years or older with stage I–III keratoconus
500 mg90 days19
21 days of mammalian omega-3 fatty acid supplementation improves aspects of neuromuscular function and performance in male athletes compared to olive oil placebo
2015 · N-3 PUFA · Healthy male athletes competing in summer Olympic sports; ages not otherwise specified
1.02 g3 weeks18
An adaptogenic role for omega-3 fatty acids in stress; a randomised placebo controlled double blind intervention study (pilot) [ISRCTN22569553]
2004 · Active (fish oil) · University staff aged 18–60 with moderate to high perceived stress
504 mg6 weeks16
A High Omega-3 Fatty Acid Multinutrient Supplement Benefits Cognition and Mobility in Older Women: A Randomized, Double-blind, Placebo-controlled Pilot Study
2016 · Efalex Active 50+ intervention · Women aged 60 years and older, community-dwelling and able to walk at least 50 m and negotiate stairs independently; nonacutely ill
1 g24 weeks15
Effects of dietary supplementation with a combination of fish oil, bilberry extract, and lutein on subjective symptoms of asthenopia in humans
2011 · Active group · People with subjective symptoms of asthenopia; age and sex not reported
783 mg4 weeks11
Eicosapentaenoic Acid and Medium-Chain Triacylglycerol Structured Lipid Supplementation Improves Muscular Endurance Exercise Performance and Reduces Muscle Fatigue in Young Healthy Male
2025 · EPA/MCT group · Healthy young men
260 mg8 weeks10
Effects of fish oil supplementation on platelet survival and ex vivo platelet function in hypercholesterolemic patients
1999 · fish oil group (T) · Patients with hypercholesterolemia, including hyperlipoproteinemia type IIa and IIb; age and sex not reported
140 mg6 weeks—
Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial
2015 · DHA/EPA and lutein/zeaxanthin · Older adults with intermediate or late age-related macular degeneration; mean age about 73 years, both sexes
350 mg5 years—
Omega-3 and -6 fatty acid supplementation and sensory processing in toddlers with ASD symptomology born preterm: A randomized controlled trial
2017 · treatment group · Children aged 18–38 months, born at ≤29 weeks’ gestation and showing significant ASD symptoms
225 mg90 days—
EPA and DHA as markers of nutraceutical treatment response in major depressive disorder
2020 · combination nutraceutical · Adults with major depressive disorder; age and sex not reported
656 mg8 weeks—
Effects of a Long Chain n-3 Polyunsaturated Fatty Acid-rich Multi-ingredient Nutrition Supplement on Body Composition and Physical Function in Older Adults with Low Skeletal Muscle Mass
2022 · supplement (SUPP) · Community-dwelling older adults with low skeletal muscle mass; mean age 74.9 years; 18 men and 19 women in the study overall
1.5 g26 weeks—
Effects of Omega-3-6-9 fatty acid supplementation on behavior and sleep in preterm toddlers with autism symptomatology: Secondary analysis of a randomized clinical trial
2022 · omega 3-6-9 treatment group · Children aged 18–38 months, born at ≤29 weeks’ gestation, with symptoms commonly associated with autism spectrum disorder
225 mg90 days—
Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-Rich n-3 PUFA Supplementation
2025 · omega-3 group (n-3) · Postmenopausal women aged 55–70 with overweight or obesity (BMI 27.5–35 kg/m²)
1.65 g16 weeks—
Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-Rich n-3 PUFA Supplementation
2025 · omega-3 + resistance training group (n-3+RT) · Postmenopausal women aged 55–70 with overweight or obesity (BMI 27.5–35 kg/m²)
1.65 g16 weeks—
Prenatal docosahexaenoic acid effect on maternal-infant DHA-equilibrium and fetal neurodevelopment: a randomized clinical trial
2022 · 200 mg DHA group · Pregnant women aged 18 years or older with singleton pregnancies, enrolled at 12–20 weeks’ gestation; no specific diagnosis required
200 mg—150
Docosahexaenoic Acid Supplementation for Neonatal Hyperbilirubinemia: A Double-Blind, Randomized Clinical Trial
2025 · DHA group · newborn infants with neonatal hyperbilirubinemia; sex not specified
100 mg—30
Oral administration of docosahexaenoic acid attenuates interleukin-1β response and clinical course of septic neonates
2012 · G-DHA · Neonates who developed sepsis following a surgical procedure
100 mg2 weeks29
Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial
2011 · DHA 250 mg group · Children with biopsy-proven non-alcoholic fatty liver disease
250 mg26 weeks20
Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children
2013 · DHA 250 mg/day · Children with non-alcoholic fatty liver disease (age range and sex not specified)
250 mg2 years20
Macrophage Activation in Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Correlates with Hepatic Progenitor Cell Response via Wnt3a Pathway
2016 · DHA-treated patients · Children and adolescents aged 7–16 years with biopsy-proven NAFLD
250 mg548 days20
A Randomized Trial of Maternal Docosahexaenoic Acid Supplementation to Reduce Inflammation in Extremely Preterm Infants
2019 · 200 mg/day DHA group · Mothers who delivered infants born before 28 weeks’ gestation and intended to provide breast milk; infants were extremely preterm
200 mg4 weeks16
A microalgae docosahexaenoic acid supplement does not modify the influence of sex and diet on iron status in Spanish vegetarians or omnivores: A randomized placebo-controlled crossover study
2024 · microalgae DHA supplement · Spanish usual consumers of lacto-ovo vegetarian, vegan, or omnivorous diets; age and sex not specified
250 mg5 weeks—
Efficacy and tolerability of calcium, vitamin D and a plant-based omega-3 oil for osteopenia: a pilot RCT
2012 · Algal oil containing DHA · Individuals with osteopenia
400 mg1 year20
Fish oil amplifies the effect of propranolol in mild essential hypertension
1990 · Third subgroup: propranolol plus fish oil · Men with mild essential hypertension
1.1 g12 weeks16
Effects of fish oils on ex vivo B-cell responses of obese subjects upon BCR/TLR stimulation: a pilot study
2018 · FO concentrate · Obese men and women with BMI >30
1.2 g12 weeks12
The effects of supplemental fish oil on blood pressure and morning cortisol in normotensive adults: a pilot study
2012 · Fish Oil (FO) · Adults, mean age 35±13 years, normotensive
800 mg6 weeks—
Effect of medium-term supplementation with a moderate dose of n-3 polyunsaturated fatty acids on blood pressure in mild hypertensive patients
1998 · EPA and DHA ethyl esters · Mild essential hypertensive, non-diabetic, normolipidemic male outpatients and normotensive male controls
1.4 g120 days—
Omega-3 fatty acid deficiency in infants before birth identified using a randomized trial of maternal DHA supplementation in pregnancy
2014 · DHA group · Pregnant women enrolled at ≤16 weeks’ gestation, without pregnancy or fetal complications and not taking lipid or fatty-acid supplements
400 mg—132
Daily Enteral DHA Supplementation Alleviates Deficiency in Premature Infants
2016 · DHA · Premature infants born at 24–34 weeks’ gestational age, both sexes, at risk of DHA deficiency
50 mg34 days31
Genetic Variants in One-Carbon Metabolism and Their Effects on DHA Biomarkers in Pregnant Women: A Post-Hoc Analysis
2022 · intervention group · Healthy pregnant women aged 21–40 years, BMI <32, enrolled at 12–16 gestational weeks
200 mg—15
Docosahexaenoic Acid (DHA) Bioavailability in Humans after Oral Intake of DHA-Containing Triacylglycerol or the Structured Phospholipid AceDoPC(®)
2020 · 13C-AceDoPC · Healthy men aged 60–70 years without cognitive defects
50 mg1 day3
Docosahexaenoic Acid (DHA) Bioavailability in Humans after Oral Intake of DHA-Containing Triacylglycerol or the Structured Phospholipid AceDoPC(®)
2020 · 13C-DHA-TAG · Healthy men aged 60–70 years without cognitive defects
50 mg1 day3
Supplementation with 200 mg/day docosahexaenoic acid from mid-pregnancy through lactation improves the docosahexaenoic acid status of mothers with a habitually low fish intake and of their infants
2008 · DHA-FOS group · Pregnant women enrolled at 21 weeks’ gestation with habitually low fish intake
200 mg——
Docosahexaenoic acid (DHA) supplementation of orange juice increases plasma phospholipid DHA content of children
2009 · lower dose · Healthy children aged 4–6 and 7–12 years
50 mg6 weeks—
Docosahexaenoic acid supplementation from mid-pregnancy to parturition influenced breast milk fatty acid concentrations at 1 month postpartum in Mexican women
2011 · DHA group · Pregnant women; age and condition beyond pregnancy not reported
400 mg——
The effect of fish oil supplementation on serum phospholipid fatty acids profile during pregnancy: A double blind randomized controlled trial
2017 · Fish oil supplementation group · Pregnant women aged 18–35 years
120 mg——
Effect of maternal docosahexaenoic acid (DHA) supplementation on breast milk composition
1996 · 0.4 g DHA/day group · Lactating mothers, randomised on day 5 postpartum
400 mg——
DHA, nutrient intake, and maternal characteristics as predictors of pregnancy outcomes in a randomised clinical trial of DHA supplementation
2023 · 200 mg/day DHA group · Pregnant women; ages and sex beyond being women were not specified
200 mg—524
Effect of a combination of genistein, polyunsaturated fatty acids and vitamins D3 and K1 on bone mineral density in postmenopausal women: a randomized, placebo-controlled, double-blind pilot study
2013 · geniVida bone blend (GBB) · Healthy postmenopausal women aged 45–55 years, 1–3 years since their last spontaneous menstrual bleeding
1 g26 weeks31
Fish-oil esters of plant sterols differ from vegetable-oil sterol esters in triglycerides lowering, carotenoid bioavailability and impact on plasminogen activator inhibitor-1 (PAI-1) concentrations in hypercholesterolemic subjects
2007 · PS-FO · Men and postmenopausal women aged 30–65 years with mildly overweight hypercholesterolemia
3.7 g4 weeks21
Effects of prenatal docosahexaenoic acid supplementation on offspring cardiometabolic health at 11 years differs by maternal single nucleotide polymorphism rs174602: follow-up of a randomized controlled trial in Mexico
2023 · DHA · Pregnant females; offspring were assessed at age 11 years
400 mg—160
Dietary supplementation with polyunsaturated fatty acid during pregnancy modulates DNA methylation at IGF2/H19 imprinted genes and growth of infants
2014 · DHA-supplemented group · Mexican pregnant women; age and condition beyond pregnancy not reported
400 mg—131
Infant Metabolome in Relation to Prenatal DHA Supplementation and Maternal Single-Nucleotide Polymorphism rs174602: Secondary Analysis of a Randomized Controlled Trial in Mexico
2021 · DHA · Pregnant women aged 18–35 years
400 mg—58
DHA supplementation during pregnancy and lactation affects infants' cellular but not humoral immune response
2011 · DHA supplementation group · Pregnant women aged 20–35 years in their third or later pregnancy; infants were exclusively breast-fed through 4 months of age
400 mg—30
Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial
2011 · DHA 500 mg group · Children with biopsy-proven non-alcoholic fatty liver disease
500 mg26 weeks20
Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children
2013 · DHA 500 mg/day · Children with non-alcoholic fatty liver disease (age range and sex not specified)
500 mg2 years20
Moderate oral supplementation with docosahexaenoic acid improves platelet function and oxidative stress in type 2 diabetic patients
2015 · DHA supplementation · Post-menopausal women with type 2 diabetes
400 mg2 weeks11
The effects of low dose n-3 fatty acids on serum lipid profiles and insulin resistance of the elderly: a randomized controlled clinical trial
2010 · intervention group · Elderly Iranian residents aged 65 or older
120 mg26 weeks—
Eicosapentaenoic and docosahexaenoic acid supplementations reduce platelet aggregation and hemostatic markers differentially in men and women
2013 · EPA-rich oil capsules · Healthy men and women
200 mg4 weeks—
Modulation of DNA methylation states and infant immune system by dietary supplementation with ω-3 PUFA during pregnancy in an intervention study
2013 · ω-3 PUFA-supplemented group · Mexican pregnant women
400 mg——
Blood lipids profile in hyperlipidemic children undergoing different dietary long chain polyunsaturated supplementations: a preliminary clinical trial
2014 · DHA alone · Children aged 8–13 years with primary hyperlipidemia
500 mg16 weeks—
Effect of omega-3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial
2014 · eicosapentaenoic acid-docosahexaenoic acid group · Patients aged 60–80 years with a history of myocardial infarction; 81% were men.
159 mg1200 days—
Docosahexaenoic acid-rich algae oil supplementation on breast milk fatty acid profile of mothers who delivered prematurely: a randomized clinical trial
2021 · S-DHA group · Mothers aged 23–28 weeks’ gestation at delivery who intended to breastfeed, with very preterm infants
1.2 g—196
Effect of APOE Genotype on Plasma Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid, Arachidonic Acid, and Hippocampal Volume in the Alzheimer's Disease Cooperative Study-Sponsored DHA Clinical Trial
2020 · DHA arm · Adults with mild Alzheimer’s disease; age range and sex not specified
2 g547 days161
Supplementation with high-dose docosahexaenoic acid increases the Omega-3 Index more than high-dose eicosapentaenoic acid
2017 · DHA treatment phase · Men and women with abdominal obesity and subclinical inflammation; ages not reported
2.7 g10 weeks154
Docosahexaenoic acid (DHA) supplementation in pregnancy differentially modulates arachidonic acid and DHA status across FADS genotypes in pregnancy
2015 · DHA · Pregnant women aged 16 to 35.99 years, enrolled at 8 to 20 weeks of gestation, who were low consumers of DHA-containing foods
600 mg26 weeks109
Efficacy of docosahexaenoic acid-enriched formula to enhance maternal and fetal blood docosahexaenoic acid levels: Randomized double-blinded placebo-controlled trial of pregnant women with gestational diabetes mellitus
2016 · active-group · Pregnant women with gestational diabetes mellitus
600 mg—58
The Dose-Response Effect of Docosahexaenoic Acid on the Omega-3 Index in American Football Athletes
2023 · 2G · NCAA Division I American-style football athletes
2 g27 weeks18
The Dose-Response Effect of Docosahexaenoic Acid on the Omega-3 Index in American Football Athletes
2023 · 6G · NCAA Division I American-style football athletes
6 g27 weeks18
The Dose-Response Effect of Docosahexaenoic Acid on the Omega-3 Index in American Football Athletes
2023 · 4G · NCAA Division I American-style football athletes
4 g27 weeks15
Bioequivalence of Docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food
2007 · DHASCO-T capsules, 600 mg DHA/day · Adults; age, sex, and health condition not specified
600 mg4 weeks12
Bioequivalence of Docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food
2007 · DHASCO-T capsules, 1,000 mg DHA/day · Adults; age, sex, and health condition not specified
1 g4 weeks12
Bioequivalence of Docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food
2007 · DHASCO-S capsules, 600 mg DHA/day · Adults; age, sex, and health condition not specified
600 mg4 weeks12
Bioequivalence of Docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food
2007 · DHASCO-S capsules, 1,000 mg DHA/day · Adults; age, sex, and health condition not specified
1 g4 weeks12
Randomized controlled trial of docosahexaenoic acid supplementation in midwestern U.S. human milk donors
2013 · DHA group · Lactating human milk donors; median age 31 years; no diagnosed condition reported
1 g—10
Effects of docosahexaenoic supplementation and in vitro vitamin C on the oxidative and inflammatory neutrophil response to activation
2015 · supplemented group · Male professional and federated football players, mean age 19.7 years; highly trained footballers
1.14 g8 weeks9
Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study
2006 · algal oil providing DHA · patients with cystic fibrosis, aged 8 to 20 years
50 mg/kg26 weeks—
Docosahexaenoic acid supplementation in vegetarians effectively increases omega-3 index: a randomized trial
2005 · DHA supplementation · Healthy adult vegetarians, 87 women and 17 men
940 mg8 weeks—
The influence of supplemental lutein and docosahexaenoic acid on serum, lipoproteins, and macular pigmentation
2008 · DHA · Women aged 60–80 years
800 mg120 days—
Algal-oil capsules and cooked salmon: nutritionally equivalent sources of docosahexaenoic acid
2008 · Algal-oil capsules · Healthy men and women aged 20–65 years
600 mg2 weeks—
Toddler formula supplemented with docosahexaenoic acid (DHA) improves DHA status and respiratory health in a randomized, double-blind, controlled trial of US children less than 3 years of age
2010 · 43 mg DHA per day · Children aged 18–36 months, with no condition stated
43 mg60 days—
DHA supplementation and pregnancy outcomes
2013 · DHA group · Pregnant women, from before 20 weeks of gestation until birth
600 mg——
The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease
2016 · DHA treatment group · Adults with probable Alzheimer’s disease, eligible with an MMSE score of 14–26; age and sex not specified
2 g548 days—
Combined choline and DHA supplementation: a randomized controlled trial
2020 · DHA supplementation · Preterm infants born before 32 weeks postmenstrual age
60 mg/kg10 days—
Compound-specific isotope analysis reveals no retroconversion of DHA to EPA but substantial conversion of EPA to DHA following supplementation: a randomized control trial
2019 · DHA group · Adults aged 21.6 ± 2.2 years; no condition stated
3 g12 weeks—
A self-emulsifying Omega-3 ethyl ester formulation (AquaCelle) significantly improves eicosapentaenoic and docosahexaenoic acid bioavailability in healthy adults
2020 · SEDDS AquaCelle fish oil formulation · Healthy adults
204 mg1 day—
A self-emulsifying Omega-3 ethyl ester formulation (AquaCelle) significantly improves eicosapentaenoic and docosahexaenoic acid bioavailability in healthy adults
2020 · Unformulated fish oil EE control · Healthy adults
204 mg1 day—
Different metabolism of EPA, DPA and DHA in humans: A double-blind cross-over study
2020 · DHA · Healthy women; age range not reported
1 g6 days—
Effect of maternal docosahexaenoic acid (DHA) supplementation on breast milk composition
1996 · 0.9 g DHA/day group · Lactating mothers, randomised on day 5 postpartum
900 mg——
Effect of maternal docosahexaenoic acid (DHA) supplementation on breast milk composition
1996 · 1.3 g DHA/day group · Lactating mothers, randomised on day 5 postpartum
1.3 g——
Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial
1997 · 1.25 g/day DHA · People with combined hyperlipidemia
1.25 g6 weeks—
Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial
1997 · 2.5 g/day DHA · People with combined hyperlipidemia
2.5 g6 weeks—
Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men
1997 · DHA oil group · Healthy men aged 19–32 years
1.68 g14 weeks—
Reproductive state and choline intake influence enrichment of plasma lysophosphatidylcholine-DHA: a post hoc analysis of a controlled feeding trial
2019 · 930 mg choline per day group · Healthy non-pregnant, third-trimester pregnant, and lactating women; reproductive groups were included in the analysis
200 mg12 weeks—
A randomized, crossover, head-to-head comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women: the Comparing EPA to DHA (ComparED) Study
2016 · DHA · Men and women with abdominal obesity and low-grade systemic inflammation, at risk of cardiovascular disease
2.7 g10 weeks154
Prenatal docosahexaenoic acid effect on maternal-infant DHA-equilibrium and fetal neurodevelopment: a randomized clinical trial
2022 · 800 mg DHA group · Pregnant women aged 18 years or older with singleton pregnancies, enrolled at 12–20 weeks’ gestation; no specific diagnosis required
800 mg—150
The triglyceride-lowering effects of a modest dose of docosahexaenoic acid alone versus in combination with low dose eicosapentaenoic acid in patients with coronary artery disease and elevated triglycerides
2006 · DHA group · Adults with coronary artery disease and triglycerides greater than 200 mg/dL
1 g8 weeks57
COMBINED INTRAVITREAL RANIBIZUMAB AND ORAL SUPPLEMENTATION WITH DOCOSAHEXAENOIC ACID AND ANTIOXIDANTS FOR DIABETIC MACULAR EDEMA: Two-Year Randomized Single-Blind Controlled Trial Results
2017 · DHA supplementation group · Patients with diabetic macular edema
1.05 g2 years29
Effects of oral eicosapentaenoic acid versus docosahexaenoic acid on human peripheral blood mononuclear cell gene expression
2015 · DHA group · Men and postmenopausal women aged 21–70 with mildly elevated plasma Lp-PLA2
1.8 g6 weeks26
Effects of lutein and docosahexaenoic Acid supplementation on macular pigment optical density in a randomized controlled trial
2013 · intervention group · Adults with early age-related macular degeneration; mean age 69.2 years, both sexes
280 mg1 year23
Docosahexaenoic acid (DHA) supplementation attenuates changes in the concentration, phenotype, and response of immune peripheral blood cells in breast cancer patients undergoing neoadjuvant therapy. Secondary findings from the DHA-WIN trial
2025 · DHA · Women with breast cancer undergoing neoadjuvant therapy; age range not specified
4.4 g18 weeks23
Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trial
2025 · DHA group · Women with newly diagnosed invasive breast cancer, stages I–III, for whom neoadjuvant chemotherapy was recommended; age range not stated
4.4 g18 weeks23
The effects of docosahexaenoic acid (DHA) on plasma cytokines, oxylipins, and tumor-infiltrating lymphocytes from women with breast cancer undergoing neoadjuvant chemotherapy in the DHA-WIN trial
2025 · DHA group · Women with breast cancer undergoing neoadjuvant chemotherapy
4.4 g18 weeks23
A comparison of the changes in cardiac output and systemic vascular resistance during exercise following high-fat meals containing DHA or EPA
2012 · DHA meal · Healthy adult males
4.7 g1 day22
EPA and DHA differentially modulate monocyte inflammatory response in subjects with chronic inflammation in part via plasma specialized pro-resolving lipid mediators: A randomized, double-blind, crossover study
2021 · DHA supplementation · Men and postmenopausal women aged 50–75 years with chronic inflammation
3 g10 weeks21
Sex differences in lipid mediators derived from omega-3 fatty acids in older individuals with low-grade chronic inflammation
2024 · DHA supplementation phase · Adults aged 50–75 years with low-grade chronic inflammation and at least one metabolic syndrome characteristic; postmenopausal women and men
3 g10 weeks21
Co-supplementation of healthy women with fish oil and evening primrose oil increases plasma docosahexaenoic acid, gamma-linolenic acid and dihomo-gamma-linolenic acid levels without reducing arachidonic acid concentrations
2008 · FSO/EPO blend · Non-pregnant women; age range and health details beyond non-pregnant are not reported
456 mg8 weeks20
EPA + DHA supplementation reduces PMN activation in microenvironment of chronic venous leg ulcers: A randomized, double-blind, controlled study
2017 · EPA + DHA Group · Men and women aged 18–81 with chronic venous leg ulcers present for at least 3 months
500 mg8 weeks20
A Randomized Double-Blinded, Placebo-Controlled Trial Investigating the Effect of Fish Oil Supplementation on Gene Expression Related to Insulin Action, Blood Lipids, and Inflammation in Gestational Diabetes Mellitus-Fish Oil Supplementation and Gestational Diabetes
2018 · omega-3 · Women aged 18–40 with gestational diabetes mellitus and no prior history of diabetes
240 mg6 weeks20
Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy
2004 · DHA supplement, women receiving HRT · Postmenopausal women receiving hormone replacement therapy
2.8 g4 weeks18
High-fat meals rich in EPA plus DHA compared with DHA only have differential effects on postprandial lipemia and plasma 8-isoprostane F2α concentrations relative to a control high-oleic acid meal: a randomized controlled trial
2014 · AO meal (high n−3 PUFA, DHA-only) · Healthy, nonsmoking men aged 35–70 years with plasma triacylglycerol concentrations >1.2 mmol/L
10.5 g1 day16
Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy
2004 · DHA supplement, women not receiving HRT · Postmenopausal women not receiving hormone replacement therapy
2.8 g4 weeks14
Effects of docosahexaenoic acid supplementation on blood lipids, estrogen metabolism, and in vivo oxidative stress in postmenopausal vegetarian women
2006 · DHA-rich algae oil group · Postmenopausal vegetarian women
2.14 g6 weeks14
The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans
2002 · DHA · Dyslipidemic subjects
3 g7 weeks12
A Randomized Trial of Maternal Docosahexaenoic Acid Supplementation to Reduce Inflammation in Extremely Preterm Infants
2019 · 1000 mg/day DHA group · Mothers who delivered infants born before 28 weeks’ gestation and intended to provide breast milk; infants were extremely preterm
1 g4 weeks11
The Efficacy of MAG-DHA for Correcting AA/DHA Imbalance of Cystic Fibrosis Patients
2018 · MAG-DHA group · Adults aged 18–48 with cystic fibrosis
3.2 g60 days10
Effects of dietary Docosahexaenoic, training and acute exercise on lipid mediators
2016 · experimental beverage · Male soccer players, mean age 19.7 years, without a stated diagnosed condition
1.14 g8 weeks9
A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects
2017 · Study 103: DHA with salsalate · Healthy adults aged 18–55 years
1.4 g1 day8
The effect of docosahexaenoic acid on plasma catecholamine concentrations and glucose tolerance during long-lasting psychological stress: a double-blind placebo-controlled study
1999 · DHA group · Medical students undergoing final exams; age not reported
1.5 g9 weeks7
Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on fatty acid absorption, incorporation into serum phospholipids and postprandial triglyceridemia
1998 · DHA group · Healthy volunteers; age and sex not specified
4 g5 weeks7
Effect of docosahexaenoic acid administration on plasma lipid profile and metabolic parameters of children with methylmalonic acidaemia
2006 · DHA administration · Children with isolated methylmalonic acidaemia (MMA), mut(0); ages and sex not specified for this arm
25 mg/kg—4
Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men
2000 · DHA group · Overweight, nonsmoking, mildly hyperlipidemic men; age range not reported
4 g6 weeks—
Dietary supplementation with eicosapentaenoic acid, but not with other long-chain n-3 or n-6 polyunsaturated fatty acids, decreases natural killer cell activity in healthy subjects aged >55 y
2001 · DHA group · Healthy adults aged 55–75 years
720 mg12 weeks—
Dietary supplementation with eicosapentaenoic acid, but not with other long-chain n-3 or n-6 polyunsaturated fatty acids, decreases natural killer cell activity in healthy subjects aged >55 y
2001 · Fish oil group · Healthy adults aged 55–75 years
280 mg12 weeks—
Dietary supplementation with gamma-linolenic acid or fish oil decreases T lymphocyte proliferation in healthy older humans
2001 · DHA group · Healthy adults aged 55–75 years
720 mg12 weeks—
Influence of dietary supplementation with long-chain n-3 or n-6 polyunsaturated fatty acids on blood inflammatory cell populations and functions and on plasma soluble adhesion molecules in healthy adults
2001 · DHA · Healthy adults aged 55–75 years
700 mg12 weeks—
Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension
2002 · DHA group · Adults with type 2 diabetes and treated hypertension; mean age 61.2 years among completers; men and postmenopausal women
4 g6 weeks—
Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients
2003 · DHA group · Treated-hypertensive men and postmenopausal women with type 2 diabetes
4 g6 weeks—
Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance
2003 · DHA group · Healthy subjects; age and sex not reported
4 g4 weeks—
Linoleate inhibits EPA incorporation from dietary fish-oil supplements in human subjects
1992 · Group H · Healthy men; age not reported; maintained on a high-linoleic-acid diet with saturated fatty acids kept low
320 mg4 weeks—
Linoleate inhibits EPA incorporation from dietary fish-oil supplements in human subjects
1992 · Group L · Healthy men; age not reported; maintained on a low-linoleic-acid, low-saturate diet
320 mg4 weeks—
Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects
2003 · purified DHA · Adults with treated hypertension and type 2 diabetes; mean age 61.2 years
4 g6 weeks—
Triacylglycerol-rich lipoprotein margination: a potential surrogate for whole-body lipoprotein lipase activity and effects of eicosapentaenoic and docosahexaenoic acids
2004 · docosahexaenoic acid (DHA) · healthy subjects; age and sex not stated
4 g4 weeks—
Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on the oxidizability and thrombogenicity of low-density lipoprotein
2004 · DHA-rich oil · Healthy human volunteers; age and sex not specified
9 g4 weeks—
Circulating triacylglycerol and apoE levels in response to EPA and docosahexaenoic acid supplementation in adult human subjects
2004 · DHA-rich oil · normolipidaemic adult subjects
4.9 g4 weeks—
Effect of docosahexaenoic acid on lipoprotein subclasses in hyperlipidemic children (the EARLY study)
2005 · docosahexaenoic acid · children with hyperlipidemia
1.2 g6 weeks—
Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol
2005 · DHA supplemented group · Men and women aged 21–80 years with below-average HDL cholesterol concentrations
1.52 g6 weeks—
Microalgal docosahexaenoic acid decreases plasma triacylglycerol in normolipidaemic vegetarians: a randomised trial
2006 · microalgae oil group · normolipidaemic adult vegetarians; 87 females and 27 males across the study
940 mg8 weeks—
Docosahexaenoic acid supply in pregnancy affects placental expression of fatty acid transport proteins
2006 · 500 mg DHA + 400 microg 5-methyl-tetrahydrofolic acid · Healthy pregnant women during the second half of gestation
500 mg——
Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men
2007 · DHA oil · Men aged 39–66 years with hypertriglyceridemia
3 g90 days—
Docosahexaenoic acid supplementation decreases remnant-like particle-cholesterol and increases the (n-3) index in hypertriglyceridemic men
2008 · DHA oil · Men aged 39–66 years with hypertriglyceridemia
3 g90 days—
Dietary alpha-linolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans
2009 · DHA group · Healthy normolipidemic men and women aged 19–43 years
2.3 g6 weeks—
The omega-3 fatty acids EPA and DHA decrease plasma F(2)-isoprostanes: Results from two placebo-controlled interventions
2010 · DHA · Overweight, dyslipidaemic men (Study A) and treated-hypertensive patients with type 2 diabetes (Study B)
4 g6 weeks—
Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults
2011 · DHA-supplemented group · Overweight or obese adults
2 g135 days—
Margarines fortified with α-linolenic acid, eicosapentaenoic acid, or docosahexaenoic acid alter the fatty acid composition of erythrocytes but do not affect the antioxidant status of healthy adults
2012 · DHA margarine group · Healthy men and women; age range and sex-specific numbers not reported
2.3 g6 weeks—
DHA-enriched high-oleic acid canola oil improves lipid profile and lowers predicted cardiovascular disease risk in the canola oil multicenter randomized controlled trial
2014 · CanolaDHA · Volunteers with abdominal obesity
60 g4 weeks—
Effect of DHA on plasma fatty acid availability and oxidative stress during training season and football exercise
2014 · experimental and supplemented group · Male football players; ages and health conditions not specified
1.14 g8 weeks—
Docosahexaenoic acid affects markers of inflammation and muscle damage after eccentric exercise
2014 · DHA · Untrained men; age and health condition not stated
2 g4 weeks—
Benefits of foods supplemented with vegetable oils rich in α-linolenic, stearidonic or docosahexaenoic acid in hypertriglyceridemic subjects: a double-blind, randomized, controlled trail
2015 · Docosahexaenoic acid (DHA) group · Hypertriglyceridemic subjects with triglycerides ≥ 1.5 mmol/L; age and sex not stated
2 g10 weeks—
Docosahexaenoic acid-enriched canola oil increases adiponectin concentrations: a randomized crossover controlled intervention trial
2015 · CanolaDHA (DHA-enriched high oleic canola oil) · Adult men and women with abdominal obesity and at least one other criterion for metabolic syndrome
60 g4 weeks—
Effect of Docosahexaenoic Acid on a Biomarker of Head Trauma in American Football
2016 · 2 g·d DHA group · NCAA Division I American football athletes
2 g27 weeks—
Effect of Docosahexaenoic Acid on a Biomarker of Head Trauma in American Football
2016 · 4 g·d DHA group · NCAA Division I American football athletes
4 g27 weeks—
Effect of Docosahexaenoic Acid on a Biomarker of Head Trauma in American Football
2016 · 6 g·d DHA group · NCAA Division I American football athletes
6 g27 weeks—
Docosahexaenoic diet supplementation, exercise and temperature affect cytokine production by lipopolysaccharide-stimulated mononuclear cells
2016 · experimental group · Male soccer players; age and health condition not reported
1.16 g8 weeks—
Elevated prostaglandin E metabolites and abnormal plasma fatty acids at baseline in pediatric cystic fibrosis patients: a pilot study
2016 · high-dose DHA · Children aged 6 to under 18 years with cystic fibrosis and baseline FEV1 greater than 40% predicted
35 mg/kg4 weeks—
Elevated prostaglandin E metabolites and abnormal plasma fatty acids at baseline in pediatric cystic fibrosis patients: a pilot study
2016 · low-dose DHA · Children aged 6 to under 18 years with cystic fibrosis and baseline FEV1 greater than 40% predicted
25 mg/kg4 weeks—
Effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular disease risk factors: a randomized clinical trial
2016 · DHA 600mg/d · Healthy, normolipidemic subjects; age and sex not specified
600 mg6 weeks—
Inflammatory gene expression in whole blood cells after EPA vs. DHA supplementation: Results from the ComparED study
2017 · DHA · Men and women with abdominal obesity and low-grade inflammation, at risk for cardiometabolic diseases
2.7 g10 weeks—
Impact of Docosahexaenoic Acid Therapy on Subgingival Plaque Microbiota
2017 · DHA group · Adults with moderate-to-severe periodontitis
2 g90 days—
Comparing the serum TAG response to high-dose supplementation of either DHA or EPA among individuals with increased cardiovascular risk: the ComparED study
2019 · DHA · Men and women with increased cardiovascular risk
2.7 g10 weeks—
EPA and DHA have divergent effects on serum triglycerides and lipogenesis, but similar effects on lipoprotein lipase activity: a randomized controlled trial
2019 · DHA group · Young, healthy normolipidemic men and women
3 g12 weeks—
Time Course and Sex Effects of α-Linolenic Acid-Rich and DHA-Rich Supplements on Human Plasma Oxylipins: A Randomized Double-Blind Crossover Trial
2021 · DHA-rich supplement · Healthy men and women aged 19–34 years with BMI 18–28 kg/m²
4 g4 weeks—
Oils Rich in α-Linolenic Acid or Docosahexaenoic Acid Have Distinct Effects on Plasma Oxylipin and Adiponectin Concentrations and on Monocyte Bioenergetics in Women with Obesity
2021 · DHA-rich fish oil · Women aged 20–51 with obesity (BMI 30–51 kg/m²)
4 g4 weeks—
Increases in plasma n-3 tetracosapentaenoic acid and tetracosahexaenoic acid following 12 weeks of EPA, but not DHA, supplementation in women and men
2022 · DHA supplemented group · Women and men aged 19–30 years
3 g12 weeks—
Monocyte transcriptomic profile following EPA and DHA supplementation in men and women with low-grade chronic inflammation
2024 · DHA supplementation · Men and postmenopausal women aged 50–75 years with chronic low-grade inflammation and at least one cardiometabolic risk characteristic
3 g10 weeks—
Omega-3 fatty acids supplements for dry eye - Are they effective or ineffective?
2023 · O3FA group · Symptomatic visual display terminal users with dry eye; mean age 26.5 years; men and women
240 mg180 days470
Sex, Body Mass Index, and APOE4 Increase Plasma Phospholipid-Eicosapentaenoic Acid Response During an ω-3 Fatty Acid Supplementation: A Secondary Analysis
2024 · ω-3 FA supplemented group · Healthy adults aged 20–80 years, men and women
800 mg26 weeks92
Evaluation of a High Concentrate Omega-3 for Correcting the Omega-3 Fatty Acid Nutritional Deficiency in Non-Alcoholic Fatty Liver Disease (CONDIN)
2018 · MF4637 omega-3 concentrate · Adults aged 18 years or older with suspected non-alcoholic fatty liver disease (NAFLD)
1.14 g24 weeks87
Multiple Micronutrients and Docosahexaenoic Acid Supplementation during Pregnancy: A Randomized Controlled Study
2020 · MMS group · Healthy pregnant Caucasian women aged 18–42 years with singleton pregnancies
200 mg27 weeks87
Efficacy of a unique omega-3 formulation on the correction of nutritional deficiency and its effects on cardiovascular disease risk factors in a randomized controlled VASCAZEN(®) REVEAL Trial
2014 · 6:1-OM3 · Adult men and women with one or more cardiovascular disease risk factors, blood Omega-Score below 6.1%, and triglycerides 1.02–5.65 mmol/L
440 mg8 weeks56
Maternal docosahexaenoic acid supplementation and fetal accretion
2003 · fish-oil capsules containing DHA · Pregnant mothers from 15 weeks gestation until term
200 mg—50
Supplementation of EPA and DHA in pregnant women with type 1 diabetes mellitus
2021 · intervention group · Pregnant women aged 17–35 with type 1 diabetes mellitus and well-controlled glycaemia; supplementation began at 11–12 gestational weeks
616 mg—42
Habitual diets rich in dark-green vegetables are associated with an increased response to ω-3 fatty acid supplementation in Americans of African ancestry
2014 · EPA + DHA supplementation · Participants of African ancestry; age and sex not stated
1 g6 weeks41
Effect of docosahexaenoic acid-enriched fish oil supplementation in pregnant women with Type 2 diabetes on membrane fatty acids and fetal body composition--double-blinded randomized placebo-controlled trial
2014 · fish oil, women with Type 2 diabetes · Pregnant women with Type 2 diabetes
600 mg—41
Effects of a convenience drink fortified with n-3 fatty acids on the n-3 index
2010 · n-3 fatty acid drink · Adults with atherosclerotic disease and an n-3 index below 5%
300 mg8 weeks40
Predictors of change in omega-3 index with fish oil supplementation in peripheral artery disease
2017 · fish oil group · Adults with stable, mild or severe claudication due to peripheral arterial disease (Rutherford Class 1 to 3); primarily male, in their mid-sixties
1.8 g30 days40
Comparative Bioavailability of DHA and EPA from Microalgal and Fish Oil in Adults
2025 · microalgal oil arm · Adults aged 21–82, men and women, with fasting triglycerides of 149–450 mg/dL
1.77 g14 weeks37
Compared with daily, weekly n-3 PUFA intake affects the incorporation of eicosapentaenoic acid and docosahexaenoic acid into platelets and mononuclear cells in humans
2014 · 2 continuous portions (2C) group · Adults aged 20–79 years, men and women, who reported no habitual oily-fish consumption and had no stated chronic clinical condition
506 mg1 year35
Safety assessment of docosahexaenoic acid in X-linked retinitis pigmentosa: the 4-year DHAX trial
2014 · DHA · Males aged 7–31 years with X-linked retinitis pigmentosa
30 mg/kg4 years33
Effect of Vitamin D and Docosahexaenoic Acid Co-Supplementation on Vitamin D Status, Body Composition, and Metabolic Markers in Obese Children: A Randomized, Double Blind, Controlled Study
2022 · GROUP I (vitamin D + DHA) · Children aged 6–14 years with obesity and vitamin D deficiency
500 mg26 weeks33
Bioavailability of long chain omega-3 polyunsaturated fatty acids from phospholipid-rich herring roe oil in men and women with mildly elevated triacylglycerols
2016 · PL-rich herring roe oil (Romega® 30) · Adults with fasting triacylglycerol concentrations of 100–399 mg/dL; men and women
1.81 g2 weeks32
Bioavailability of long chain omega-3 polyunsaturated fatty acids from phospholipid-rich herring roe oil in men and women with mildly elevated triacylglycerols
2016 · TAG-rich fish oil · Adults with fasting triacylglycerol concentrations of 100–399 mg/dL; men and women
1.84 g2 weeks32
Compared with daily, weekly n-3 PUFA intake affects the incorporation of eicosapentaenoic acid and docosahexaenoic acid into platelets and mononuclear cells in humans
2014 · 2 intermittent portions (2I) group · Adults aged 20–79 years, men and women, who reported no habitual oily-fish consumption and had no stated chronic clinical condition
506 mg1 year30
Bioequivalence of long-chain omega-3 polyunsaturated fatty acids from foods enriched with a novel vegetable-based omega-3 delivery system compared to gel capsules: a randomized controlled cross-over acute trial
2022 · Soup · Apparently healthy men aged 21–50 years, Australian European or Singaporean Chinese
400 mg1 day27
Bioequivalence of long-chain omega-3 polyunsaturated fatty acids from foods enriched with a novel vegetable-based omega-3 delivery system compared to gel capsules: a randomized controlled cross-over acute trial
2022 · Extruded rice snack · Apparently healthy men aged 21–50 years, Australian European or Singaporean Chinese
400 mg1 day27
Bioequivalence of long-chain omega-3 polyunsaturated fatty acids from foods enriched with a novel vegetable-based omega-3 delivery system compared to gel capsules: a randomized controlled cross-over acute trial
2022 · Gel capsule (control) · Apparently healthy men aged 21–50 years, Australian European or Singaporean Chinese
400 mg1 day27
Influence of Fish Consumption and ω-3 Supplementation on the ω-3 Index of Young Adults: A 2 × 2 Factorial Randomized Controlled Trial (YouFish Study)
2025 · ω-3 supplement · Healthy young adults aged 18–30 years, male and female, low habitual fish consumers with ω-3 index <6%
300 mg8 weeks20
Comparative Bioavailability of DHA and EPA from Microalgal and Fish Oil in Adults
2025 · fish oil arm · Adults aged 21–82, men and women, with fasting triglycerides of 149–450 mg/dL
820 mg14 weeks20
Wax Ester Rich Oil From The Marine Crustacean, Calanus finmarchicus, is a Bioavailable Source of EPA and DHA for Human Consumption
2016 · Calanus Oil condition · Healthy adults; age and sex not specified
156 mg1 day18
Wax Ester Rich Oil From The Marine Crustacean, Calanus finmarchicus, is a Bioavailable Source of EPA and DHA for Human Consumption
2016 · Lovaza ethyl ester condition · Healthy adults; age and sex not specified
375 mg1 day18
Prenatal choline supplementation improves biomarkers of maternal docosahexaenoic acid (DHA) status among pregnant participants consuming supplemental DHA: a randomized controlled trial
2022 · Control group · Pregnant participants aged 21–40 years, enrolled at 12–16 weeks’ gestation, without the specified health conditions or pregnancy complications
200 mg169 days15
Genetic Variants in One-Carbon Metabolism and Their Effects on DHA Biomarkers in Pregnant Women: A Post-Hoc Analysis
2022 · control group · Healthy pregnant women aged 21–40 years, BMI <32, enrolled at 12–16 gestational weeks
200 mg—15
Dietary substitution with an alpha-linolenic acid-rich vegetable oil increases eicosapentaenoic acid concentrations in tissues
1994 · flaxseed group · Healthy adult men; age range not reported
1.08 g8 weeks15
Dietary substitution with an alpha-linolenic acid-rich vegetable oil increases eicosapentaenoic acid concentrations in tissues
1994 · control group · Healthy adult men; age range not reported
1.08 g4 weeks15
The effect of supplementation with docosahexaenoic and arachidonic acid derived from single cell oils on plasma and erythrocyte fatty acids of pregnant women in the second trimester
2000 · intervention group · Healthy pregnant women in the second trimester
570 mg4 weeks12
In vitro dissolution behaviour and absorption in humans of a novel mixed l-lysine salt formulation of EPA and DHA
2021 · Lys-FFA · Eight female volunteers
302 mg1 day8
In vitro dissolution behaviour and absorption in humans of a novel mixed l-lysine salt formulation of EPA and DHA
2021 · EE · Eight female volunteers
378 mg1 day8
Plasma fatty acid responses, metabolic effects, and safety of microalgal and fungal oils rich in arachidonic and docosahexaenoic acids in healthy adults
1996 · 1 x · healthy adult men
600 mg2 weeks8
Plasma fatty acid responses, metabolic effects, and safety of microalgal and fungal oils rich in arachidonic and docosahexaenoic acids in healthy adults
1996 · 3 x · healthy adult men
1.7 g2 weeks8
Plasma fatty acid responses, metabolic effects, and safety of microalgal and fungal oils rich in arachidonic and docosahexaenoic acids in healthy adults
1996 · 5 x · healthy adult men
2.9 g2 weeks8
Supplementation of arachidonic acid plus docosahexaenoic acid in cirrhotic patients awaiting liver transplantation: a preliminary study
2007 · AA/DHA group · Adults with end-stage liver disease awaiting liver transplantation
1 g6 weeks5
Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on immune cell composition and function in healthy humans
2004 · DHA · Healthy human subjects; age and sex not specified
4.9 g4 weeks—
Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids
2006 · fish oil · 20 study participants; age, sex, and health condition not specified
864 mg8 weeks—
Effects of fish-oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: a European randomized multicenter trial
2007 · FO · Pregnant women from gestation week 22 until delivery
500 mg——
Effects of fish-oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: a European randomized multicenter trial
2007 · FO with MTHF · Pregnant women from gestation week 22 until delivery
500 mg——
The effects of fish oil supplementation in pregnancy on breast milk fatty acid composition over the course of lactation: a randomized controlled trial
2007 · fish oil group · Pregnant women, from 20 weeks of gestation until delivery
2.2 g——
Erythrocyte and plasma fatty acid profiles in patients with epilepsy: does carbamazepine affect omega-3 fatty acid concentrations?
2008 · omega-3 FA supplementation · Patients with epilepsy; age and sex not reported
700 mg12 weeks—
The influence of supplemental lutein and docosahexaenoic acid on serum, lipoproteins, and macular pigmentation
2008 · lutein + DHA · Women aged 60–80 years
800 mg120 days—
Human milk arachidonic acid and docosahexaenoic acid contents increase following supplementation during pregnancy and lactation
2009 · AA+DHA · Women supplemented during pregnancy and lactation
220 mg——
Enhanced increase of omega-3 index in response to long-term n-3 fatty acid supplementation from triacylglycerides versus ethyl esters
2011 · rTAG group · Human volunteers; age, sex and health condition not specified
670 mg26 weeks—
Enhanced increase of omega-3 index in response to long-term n-3 fatty acid supplementation from triacylglycerides versus ethyl esters
2011 · EE group · Human volunteers; age, sex and health condition not specified
670 mg26 weeks—
Long-chain n-3 polyunsaturated fatty acid dietary recommendations are moderately efficient in optimizing their status in healthy middle-aged subjects with low fish consumption: a cross-over study
2014 · commercial fish oil supplement · Healthy middle-aged adults with low customary fish consumption
250 mg8 weeks—
Kinetics of omega-3 polyunsaturated fatty acids when co-administered with saturated or omega-6 fats
2015 · Butter meal · Healthy adult men and women
1.5 g1 day—
Kinetics of omega-3 polyunsaturated fatty acids when co-administered with saturated or omega-6 fats
2015 · Sunflower seed oil meal · Healthy adult men and women
1.5 g1 day—
Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial
2016 · unmodified fish oil TAG (uTAG) · Healthy men in the postprandial crossover study
370 mg1 day—
Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial
2016 · re-esterified TAG · Healthy men in the postprandial crossover study
370 mg1 day—
Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial
2016 · free fatty acids (FFA) · Healthy men in the postprandial crossover study
370 mg1 day—
Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial
2016 · ethyl esters (EE) · Healthy men in the postprandial crossover study
370 mg1 day—
Monoacylglycerol-enriched oil increases EPA/DHA delivery to circulatory system in humans with induced lipid malabsorption conditions
2016 · MAG-enriched oil · Obese adults (BMI 30–40 kg/m²), with and without Orlistat-induced lipid malabsorption/maldigestion
300 mg3 weeks—
Monoacylglycerol-enriched oil increases EPA/DHA delivery to circulatory system in humans with induced lipid malabsorption conditions
2016 · TAG fish oil · Obese adults (BMI 30–40 kg/m²), with and without Orlistat-induced lipid malabsorption/maldigestion
300 mg3 weeks—
Omega-3 Fatty Acid Plasma Levels Before and After Supplementation: Correlations with Mood and Clinical Outcomes in the Omega-3 and Therapy Studies
2017 · Ω3 supplementation · Children aged 7–14 with depression or bipolar disorder
200 mg12 weeks—
Omega-3 Fatty Acid Plasma Levels Before and After Supplementation: Correlations with Mood and Clinical Outcomes in the Omega-3 and Therapy Studies
2017 · PEP plus Ω3 supplementation · Children aged 7–14 with depression or bipolar disorder
200 mg12 weeks—
DHA-rich Fish Oil Increases the Omega-3 Index and Lowers the Oxygen Cost of Physiologically Stressful Cycling in Trained Individuals
2017 · DHA-rich tuna fish oil (FO) · trained males; age and health condition not specified
560 mg8 weeks—
Maternal Pre-Pregnancy Obesity Attenuates Response to Omega-3 Fatty Acids Supplementation During Pregnancy
2018 · n-3 PUFA supplementation group · Pregnant women with a history of at least one prior singleton preterm delivery, enrolled at 16 to 21 6/7 weeks; lean, overweight, and obese women were included
800 mg8 weeks—
Combined choline and DHA supplementation: a randomized controlled trial
2020 · combined choline and DHA supplementation · Preterm infants born before 32 weeks postmenstrual age
60 mg/kg10 days—
Plasma oxylipins and unesterified precursor fatty acids are altered by DHA supplementation in pregnancy: Can they help predict risk of preterm birth?
2020 · DHA supplementation group · Pregnant Australian women enrolled before 20 weeks of gestation; age and condition range not specified
800 mg——
Intake of Docosahexaenoic Acid-Enriched Milk Beverage Prevents Age-Related Cognitive Decline and Decreases Serum Bone Resorption Marker Levels
2021 · docosahexaenoic acid-enriched milk beverage · Healthy elderly Japanese individuals with a Mini-Mental State Examination score of 28 or higher at baseline
297 mg1 year—
Modification of serum fatty acids in preterm infants by parenteral lipids and enteral docosahexaenoic acid/arachidonic acid: A secondary analysis of the Mega Donna Mega trial
2023 · AA:DHA supplementation group · Extremely preterm infants born before 28 weeks’ gestation
50 mg/kg——
Effects of EPA+DHA and Corn Oil Supplementation on PUFA Concentrations across Plasma Lipid Pools and on Downstream Oxylipins: Exploratory Results from a Randomized Controlled Trial in Healthy Humans
2026 · EPA+DHA concentrate · Healthy adults aged 35–49 years; 20 women and 1 man in the available-sample analysis
800 mg12 weeks—
Comparative effects of prolonged intake of highly purified fish oils as ethyl ester or triglyceride on lipids, haemostasis and platelet function in normolipaemic men
1993 · ethyl ester (EE) · healthy normolipaemic men
1.2 g7 weeks—
Comparative effects of prolonged intake of highly purified fish oils as ethyl ester or triglyceride on lipids, haemostasis and platelet function in normolipaemic men
1993 · triglyceride (TG) · healthy normolipaemic men
1.4 g7 weeks—
Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men
1997 · fish diet group · Healthy men aged 19–32 years
670 mg14 weeks—
Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men
1997 · fish oil group · Healthy men aged 19–32 years
950 mg14 weeks—
DHA, nutrient intake, and maternal characteristics as predictors of pregnancy outcomes in a randomised clinical trial of DHA supplementation
2023 · 1000 mg/day DHA group · Pregnant women; ages and sex beyond being women were not specified
1 g—576
Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease
2015 · Active group (RCT1, RCT2 and RCT3) · Men and women aged 50 years or older with mild or mild-to-moderate Alzheimer's disease; RCT3 participants were on stable approved Alzheimer's medication, while RCT1 and RCT2 participants were drug-free for Alzheimer's medication.
1.2 g24 weeks501
Prevention of Potential Adverse Metabolic Effects of a Supplementation with Omega-3 Fatty Acids Using a Genetic Score Approach
2020 · n-3 PUFA supplementation · Adults; age, sex, and health condition not specified
1.1 g6 weeks210
Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease
2015 · Active product during open-label extension (OLE) · Men and women aged 50 years or older with mild Alzheimer's disease who completed RCT2.
1.2 g24 weeks201
Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
2017 · Lovaza · Adults aged 36–80 with stable coronary artery disease and overweight/obesity or metabolic-syndrome features; included participants with and without type 2 diabetes
1.5 g1 year147
Effect of Eicosapentaenoic and Docosahexaenoic Acids Added to Statin Therapy on Coronary Artery Plaque in Patients With Coronary Artery Disease: A Randomized Clinical Trial
2017 · Omega-3 ethyl-ester group · Adults aged 21–80 with stable coronary artery disease and overweight or metabolic risk features; predominantly men
1.5 g913 days143
Regression of Coronary Fatty Plaque and Risk of Cardiac Events According to Blood Pressure Status: Data From a Randomized Trial of Eicosapentaenoic Acid and Docosahexaenoic Acid in Patients With Coronary Artery Disease
2023 · EPA+DHA · Adults aged 37–80 years with stable coronary artery disease, on statin therapy
1.5 g913 days143
Effects of EPA, γ-linolenic acid or coenzyme Q10 on serum prostate-specific antigen levels: a randomised, double-blind trial
2013 · group 1 (n-3 fatty acids) · Healthy men with serum PSA ≤ 2.5 ng/ml
2.88 g12 weeks126
An omega-3 fatty acid plasma index ≥4% prevents progression of coronary artery plaque in patients with coronary artery disease on statin treatment
2019 · omega-3 ethyl esters (Lovaza) · Adults aged 21–80 with stable coronary artery disease, receiving statin treatment
1.5 g913 days119
Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study
2013 · n - 3/n - 3 group · Older adults with Alzheimer's disease; mean age 75 years; 57% women
1.7 g1 year89
Proteomic Profile in Retinopathy of Prematurity: A Secondary Analysis of the Mega Donna Mega Randomized Clinical Trial
2026 · AA/DHA supplementation · Extremely preterm infants born before 28 weeks’ gestational age
50 mg/kg—84
Effects of perioperative supplementation with omega-3 fatty acids on leukotriene B₄ and leukotriene B₅ production by stimulated neutrophils in patients with colorectal cancer: a randomized, placebo-controlled intervention trial
2014 · n-3 FA (active) · Adults aged 41–89 with colorectal cancer awaiting surgery
1 g7 days74
Essential Fatty Acid Supplementation and Early Inflammation in Preterm Infants: Secondary Analysis of a Randomized Clinical Trial
2023 · ARA:DHA group · Extremely preterm infants born at gestational age less than 29 weeks
50 mg/kg—60
Arachidonic and docosahexaenoic acid supplementation and brain maturation in preterm infants; a double blind RCT
2024 · ARA:DHA group · Infants born before 29 weeks gestational age
50 mg/kg—60
Effect of Oral Re-esterified Omega-3 Nutritional Supplementation on Dry Eyes
2016 · omega-3 group · Adults over 18 years with diagnosed dry eye disease, meibomian gland dysfunction stage 1 or 2, and elevated tear osmolarity
560 mg12 weeks54
ω-3 PUFA for Secondary Prevention of White Matter Lesions and Neuronal Integrity Breakdown in Older Adults: A Randomized Clinical Trial
2024 · ω-3 group · Adults aged 75 years or older with cerebral white matter lesions and suboptimal ω-3 status; cognitively intact or with mild cognitive impairment, without dementia
675 mg3 years51
Joint effects of one year of marine omega-3 fatty acid supplementation and participant dietary fish intake upon circulating lipid mediators of inflammation resolution in a randomized controlled trial
2024 · n-3 fatty acid supplementation · Women aged 55 years or older and men aged 50 years or older; participants selected from the VITAL trial by baseline fish intake, without a stated diagnosis
380 mg1 year50
Effects of Fatty Acid Therapy in Addition to Strong Statin on Coronary Plaques in Acute Coronary Syndrome: An Optical Coherence Tomography Study
2020 · EPA+DHA group · Adults with acute coronary syndrome after successful PCI; age and sex mix not restricted
750 mg1 year48
Effect of eicosapentaenoic acid and docosahexaenoic acid supplementation on C-peptide preservation in pregnant women with type-1 diabetes: randomized placebo controlled clinical trial
2017 · Study group · Pregnant women with type-1 diabetes mellitus
1.23 g—47
Platelet redox balance in diabetic patients with hypertension improved by n-3 fatty acids
2013 · n-3 PUFA / fish oil treatment · Adults with type 2 diabetes and hypertension, and adults with hypertension without diabetes; age- and sex-matched groups
380 mg8 weeks45
A randomized trial of supplementation with docosahexaenoic acid-rich tuna oil and its effects on the human milk cytokines interleukin 1 beta, interleukin 6, and tumor necrosis factor alpha
2002 · 300 mg DHA + 70 mg EPA · Lactating mothers of healthy full-term infants; age and sex beyond lactating women are not reported
300 mg4 weeks40
A randomized trial of supplementation with docosahexaenoic acid-rich tuna oil and its effects on the human milk cytokines interleukin 1 beta, interleukin 6, and tumor necrosis factor alpha
2002 · 600 mg DHA + 140 mg EPA · Lactating mothers of healthy full-term infants; age and sex beyond lactating women are not reported
600 mg4 weeks40
Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements
2017 · fish oil group · Adults aged 50 and older with symptomatic lower-extremity peripheral arterial disease and intermittent claudication
1.8 g30 days40
DHA-enriched fish oil reduces insulin resistance in overweight and obese adults
2020 · FO (fish oil) intervention · Men and women with abdominal obesity, without diabetes; mean age 50.9 ± 12.7 years
860 mg12 weeks38
Effect of prenatal EPA and DHA on maternal and umbilical cord blood cytokines
2018 · EPA-rich fish oil · Pregnant women at 12–20 weeks’ gestation with risk of depression, based on Edinburgh Postnatal Scale score 9–19 or past depression history
274 mg14 weeks37
Dietary Omega-3 Fatty Acid Supplementation Reduces Inflammation in Obese Pregnant Women: A Randomized Double-Blind Controlled Clinical Trial
2015 · ω-3 FA supplement arm · Overweight or obese pregnant women (BMI ≥25), generally healthy, enrolled at 8–16 weeks’ gestation
800 mg25 weeks36
Treatment with high-dose n-3 PUFAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes
2017 · n-3 PUFAs · Adults, mean age 65.6 years, men and women, with type 2 diabetes and established atherosclerotic cardiovascular disease
1 g90 days36
Effect of prenatal EPA and DHA on maternal and umbilical cord blood cytokines
2018 · DHA-rich fish oil · Pregnant women at 12–20 weeks’ gestation with risk of depression, based on Edinburgh Postnatal Scale score 9–19 or past depression history
900 mg14 weeks36
Dietary supplementation with docosahexaenoic acid rich fish oil increases circulating levels of testosterone in overweight and obese men
2020 · DHA-enriched fish oil (FO) · Overweight and obese men and women without diabetes; testosterone analysis focused on men
860 mg12 weeks32
DHA-rich n-3 fatty acid supplementation decreases DNA methylation in blood leukocytes: the OmegAD study
2017 · n-3 FA group · Patients with Alzheimer disease; age and sex not reported
1.7 g26 weeks30
Atherothrombogenic risk modulation by n-3 fatty acids was not associated with changes in homocysteine in subjects with combined hyperlipidaemia
1999 · n-3 fatty acids · Adults with combined (type IIb) hyperlipidaemia who had not responded to a therapeutic diet
4 g12 weeks28
Omega-3 PUFA supplementation and the response to evoked endotoxemia in healthy volunteers
2014 · Lovaza 1/day · Healthy men and non-pregnant, non-lactating women aged 18–45 years
375 mg7 weeks28
Body weight affects ω-3 polyunsaturated fatty acid (PUFA) accumulation in youth following supplementation in post-hoc analyses of a randomized controlled trial
2017 · ω-3 supplement group · Children and adolescents aged 7–14 years with mood disorders, including bipolar disorder, major depressive disorder, or dysthymic disorder
200 mg12 weeks28
Effects of an Omega-3 and Vitamin D Supplement on Fatty Acids and Vitamin D Serum Levels in Double-Blinded, Randomized, Controlled Trials in Healthy and Crohn's Disease Populations
2020 · Nutrient supplement phase, healthy participants · Healthy adults aged 20–65 years
510 mg4 weeks27
Marine ω-3 PUFA Supplementation Enhances FFAR4 Activation and Reduces Inflammatory Markers in PBMC of Subjects with Obesity: A Randomized Controlled Trial (EPICO)
2025 · marine-derived ω-3 · Adults aged 25–59 years with obesity or abdominal obesity, without major health complications
720 mg8 weeks26
Effects of low-dose omega-3 fatty acid substitution in type-2 diabetes mellitus with special reference to oxidative stress--a prospective preliminary study
2002 · group 2 (Maxigard group) · Adults with type 2 diabetes and BMI <27 kg/m²; age and sex not specified
240 mg6 weeks25
Lipid mediator serum profiles in asthmatics significantly shift following dietary supplementation with omega-3 fatty acids
2013 · ω-3 FA · Adults aged 20–54 with clinically diagnosed mild-to-moderate asthma
2 g3 weeks25
Efficacy of fish oil on serum of TNF α , IL-1 β , and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b
2013 · fish oil group · Adults aged 18–55 with relapsing-remitting multiple sclerosis, treated with interferon beta-1b
1.6 g1 year25
Omega-3 PUFA supplementation and the response to evoked endotoxemia in healthy volunteers
2014 · Lovaza 4/day · Healthy men and non-pregnant, non-lactating women aged 18–45 years
1.5 g7 weeks25
Effects of oral supplementation with omega-3 fatty acids on nutritional state and inflammatory markers in maintenance hemodialysis patients
2014 · omega-3 group · Adults undergoing maintenance hemodialysis
720 mg120 days25
Generation and dietary modulation of anti-inflammatory electrophilic omega-3 fatty acid derivatives
2014 · fish oil group (treatment) · Healthy adults aged 30–54 years, employed at least 25 hours per week, with dietary EPA and DHA consumption below 300 mg/day
400 mg120 days24
Urinary metabolite profiles in premature infants show early postnatal metabolic adaptation and maturation
2014 · intervention group · Premature infants with birth weight below 1500 g
60 mg/kg4 weeks24
Omega-3 Fatty Acid Could Increase One of Myokines in Male Patients with Coronary Artery Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
2017 · Omega-3 · Men with coronary artery disease and more than 50% stenosis in at least one major coronary vessel
480 mg8 weeks24
Cytokine distribution in mothers and breastfed children after omega-3 LCPUFAs supplementation during the last trimester of pregnancy and the lactation period: A randomized, controlled trial
2017 · FO group · Pregnant women recruited at week 28 of pregnancy and followed through lactation
320 mg—24
Hepatic de novo lipogenesis is suppressed and fat oxidation is increased by omega-3 fatty acids at the expense of glucose metabolism
2020 · omega-3 FA group · Men aged 35–55 years with fasting plasma TAG concentrations of at least 1.5 mmol/L; nondiabetic and free from known disease
1.52 g8 weeks24
Effects of an Omega-3 and Vitamin D Supplement on Fatty Acids and Vitamin D Serum Levels in Double-Blinded, Randomized, Controlled Trials in Healthy and Crohn's Disease Populations
2020 · Nutrient supplement phase, participants with Crohn's disease · Adults aged 20–65 years with Crohn’s disease in remission
510 mg6 weeks24
Metabolic and endocrine effects of long-chain versus essential omega-3 polyunsaturated fatty acids in polycystic ovary syndrome
2011 · fish oil · Women aged 20–45 with PCOS and BMI 25–45 kg/m²
1.45 g6 weeks21
Secondary data analysis investigating effects of marine omega-3 fatty acids on circulating levels of leptin and adiponectin in older adults
2021 · EPA+DHA Group · Adults aged 50–85 with chronic inflammatory conditions, including nonhealing venous leg ulcers; overweight or obese older adults
1 g8 weeks21
Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial
2016 · Treatment arm · Children and adolescents aged 4–16 years with biopsy-proven NAFLD and serum vitamin D deficiency
500 mg24 weeks20
N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial
2022 · n-3 FA · Caucasian men and women aged 50–79 with combined hyperlipidemia, taking stable atorvastatin
1 g8 weeks20
Omega-3 Fatty Acids Reduce Remnant-like Lipoprotein Cholesterol and Improve the Ankle-Brachial Index of Hemodialysis Patients with Dyslipidemia: A Pilot Study
2023 · high-dose EPA/DHA group · Adults aged 20 years or older receiving hemodialysis and diagnosed with dyslipidemia
1.5 g90 days19
The effect of highly purified eicosapentaenoic and docosahexaenoic acids on monocyte phagocytosis in man
1997 · highly purified DHA · healthy men
3.6 g7 weeks19
Dietary supplementation with fish oil in ulcerative colitis
1992 · fish oil · Adults with active ulcerative colitis
2.16 g120 days18
Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial
2020 · DHA treatment arm · Cognitively unimpaired men and women aged 55 years and older with a first-degree family history of dementia
2.15 g26 weeks18
DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men
2009 · DHA oil group · Men aged 39–66 with hypertriglyceridemia
3 g90 days17
Fish oil supplementation induces expression of genes related to cell cycle, endoplasmic reticulum stress and apoptosis in peripheral blood mononuclear cells: a transcriptomic approach
2014 · FO group · Healthy men and women aged 18–50 years
900 mg7 weeks17
Effects of Dietary n-3 Fatty Acids on Hepatic and Peripheral Insulin Sensitivity in Insulin-Resistant Humans
2015 · n-3 (EPA+DHA) · Overweight insulin-resistant, nondiabetic adults; 8 men and 23 women were randomized, ages not stated
600 mg26 weeks16
Supplementation with eicosapentaenoic acid and docosahexaenoic acid reduces high levels of circulating proinflammatory cytokines in aging adults: A randomized, controlled study
2018 · EPA+DHA Group · Men and women aged 50–85 with chronic venous leg ulcers diagnosed for at least 3 months
1 g8 weeks16
Omega-3 Fatty Acids Reduce Remnant-like Lipoprotein Cholesterol and Improve the Ankle-Brachial Index of Hemodialysis Patients with Dyslipidemia: A Pilot Study
2023 · low-dose EPA/DHA group · Adults receiving hemodialysis and diagnosed with dyslipidemia who continued after the initial control period
750 mg90 days16
Supplementation of postmenopausal women with fish oil rich in eicosapentaenoic acid and docosahexaenoic acid is not associated with greater in vivo lipid peroxidation compared with oils rich in oleate and linoleate as assessed by plasma malondialdehyde and F(2)-isoprostanes
2000 · Fish oil · Postmenopausal women
1.4 g—15
Supplementation of postmenopausal women with fish oil does not increase overall oxidation of LDL ex vivo compared to dietary oils rich in oleate and linoleate
2001 · fish oil (FO) · Postmenopausal women; ages and health conditions not specified
1.4 g—15
Omega-3 fatty acids effect on wound healing
2008 · EPA/DHA supplement group · Healthy men and women aged 18–45 years
1.1 g5 weeks15
[Metabolic syndrome reversion by polyunsaturated fatty acids ingestion]
2013 · n-3 group · Adults with metabolic syndrome
720 mg6 weeks15
Dietary supplementation with low-dose omega-3 fatty acids reduces salivary tumor necrosis factor-α levels in patients with chronic periodontitis: a randomized controlled clinical study
2017 · test group · Systemically healthy patients with chronic periodontitis; age and sex not reported
19.2 mg26 weeks15
Supplementation of Re-Esterified Docosahexaenoic and Eicosapentaenoic Acids Reduce Inflammatory and Muscle Damage Markers after Exercise in Endurance Athletes: A Randomized, Controlled Crossover Trial
2020 · DHA + EPA · Healthy male amateur endurance athletes aged 18–45 years
2.1 g10 weeks15
Prenatal choline supplementation improves biomarkers of maternal docosahexaenoic acid (DHA) status among pregnant participants consuming supplemental DHA: a randomized controlled trial
2022 · Intervention group · Pregnant participants aged 21–40 years, enrolled at 12–16 weeks’ gestation, without the specified health conditions or pregnancy complications
200 mg171 days15
An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia
2004 · Omacor · 14 patients with familial combined hyperlipidemia (FCHL); age range and sex not reported
1.48 g8 weeks14
Effects of alpha-linolenic acid versus those of EPA/DHA on cardiovascular risk markers in healthy elderly subjects
2006 · EPA/DHA-rich diet · Healthy mildly hypercholesterolemic adults aged 60–78 years, 14 men and 23 women across the study
550 mg6 weeks14
Effect of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: a randomized, placebo controlled, cross-over study
2009 · EPA/DHA · Exercise-trained men; ages 25.5 ± 4.8 years; no stated cardiovascular or metabolic disorders
2.21 g6 weeks14
Effects of dietary n-3 polyunsaturated fatty acids from plant and marine origin on platelet aggregation in healthy elderly subjects
1999 · EPA/DHA diet, elderly subjects · Adults older than 60 years, healthy elderly subjects
550 mg6 weeks13
Fatty acid absorption in preterms on formulas with and without long-chain polyunsaturated fatty acids and in terms on formulas without these added
2001 · Group PB · Preterm newborns receiving preterm formula supplemented with arachidonic acid and docosahexaenoic acid
10 mg/kg3 days13
Impact of Long-Term Supplementation with Fish Oil in Individuals with Non-Alcoholic Fatty Liver Disease: A Double Blind Randomized Placebo Controlled Clinical Trial
2020 · n-3 PUFA group · Adults aged 19 years or older, both sexes, with ultrasound-confirmed non-alcoholic fatty liver disease
1.51 mg26 weeks13
Telomere shortening in elderly individuals with mild cognitive impairment may be attenuated with ω-3 fatty acid supplementation: a randomized controlled pilot study
2014 · EPA group · Adults older than 65 years with mild cognitive impairment
160 mg26 weeks12
Telomere shortening in elderly individuals with mild cognitive impairment may be attenuated with ω-3 fatty acid supplementation: a randomized controlled pilot study
2014 · DHA group · Adults older than 65 years with mild cognitive impairment
1.55 g26 weeks12
Effects of fish oils on ex vivo B-cell responses of obese subjects upon BCR/TLR stimulation: a pilot study
2018 · High DHA-FO concentrate · Obese men and women with BMI >30
2 g12 weeks12
Effects of DHA-rich n-3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study
2012 · n-3 FA group · Patients aged 54–82 with mild to moderate Alzheimer’s disease
1.7 g26 weeks11
Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial)
2019 · fish oil group · Men aged 50 years or older with peripheral artery disease and intermittent claudication
1.8 g90 days11
Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial)
2019 · fish oil group · Men aged 50 years or older with peripheral artery disease and intermittent claudication
1.8 g90 days11
Supplementation with dietary ω-3 mitigates immobilization-induced reductions in skeletal muscle mitochondrial respiration in young women
2019 · ω-3 supplementation · Healthy young women, age 22 ± 3 years
2 g6 weeks11
The influence of low intake of n-3 fatty acids on platelets in elderly people
1999 · n-3 PUFA group · healthy elderly people; age range and sex not stated
150 mg6 weeks10
Effect of omega-3 fatty acids on rectal mucosal cell proliferation in subjects at risk for colon cancer
1992 · fish oil group · Patients with sporadic adenomatous colorectal polyps; age and sex not reported
3.6 g12 weeks10
Different gene expression profiles in normo- and dyslipidemic men after fish oil supplementation: results from a randomized controlled trial
2012 · FO-N (normolipidemic fish oil group) · Men aged 29–51 years with normolipidemia
1.14 g12 weeks10
Distal procto-colitis and n-3 polyunsaturated fatty acids: the mechanism(s) of natural cytotoxicity inhibition
2000 · fish oil extract · Patients with procto-colitis; age and sex not reported
2.4 g26 weeks9
Fish oil supplementation alters levels of lipid mediators of inflammation in microenvironment of acute human wounds
2011 · Active Group (EPA + DHA supplement) · Healthy adults aged 18–45 years, both sexes
1.2 g4 weeks9
Different gene expression profiles in normo- and dyslipidemic men after fish oil supplementation: results from a randomized controlled trial
2012 · FO-D (dyslipidemic fish oil group) · Men aged 29–51 years with dyslipidemia
1.14 g12 weeks9
[Effect of short-term use of omega-3-type polyunsaturated fatty acids in subjects with hypertriglyceridemia]
1992 · fish oil · Patients with hypertriglyceridemia; age and sex not reported
1.2 g12 weeks8
Metabolic effects of fish-oil supplementation in patients with impaired glucose tolerance
1991 · fish-oil supplementation · Obese adults with impaired glucose tolerance; mean age 50.3 years; sex not reported
2.5 g2 weeks8
Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects
1994 · fish oil · Subjects without cystic fibrosis; mean age 13.4 years
2.2 g6 weeks8
Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects
1994 · fish oil · Patients with cystic fibrosis and pancreatic insufficiency; mean age 12.2 years
2.2 g6 weeks7
Omega 3 Improves Both apoB100-containing Lipoprotein Turnover and their Sphingolipid Profile in Hypertriglyceridemia
2020 · n-3 supplementation · Six subjects with hypertriglyceridemia; age and sex not reported
240 mg60 days6
Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation
2018 · EPA and DHA (3.4 g/day) · Healthy men aged 29–32 years
1.52 g8 weeks3
Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation
2018 · 1800 mg/d EPA and DHA · Healthy adults; Study A participants aged 21–28 years, 2 men and 1 woman in the supplement group
700 mg150 days2
Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation
2018 · 900 mg/d EPA and DHA · Healthy adults; Study A participants aged 21–28 years, 2 men and 1 woman in the supplement group
350 mg150 days1
Consumption of fish oil leads to prompt incorporation of eicosapentaenoic acid into colonic mucosa of patients prior to surgery for colorectal cancer, but has no detectable effect on epithelial cytokinetics
1999 · FO group · Adults with colonic carcinoma awaiting surgery; ages and sex distribution as reported in the abstract
1 g12 days—
Encapsulated fish oil enriched in alpha-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions
2000 · fish oil (FO) · Healthy subjects; age and sex not specified
1.1 g12 weeks—
Effect of a fish-oil concentrate on serum lipids in postmenopausal women receiving and not receiving hormone replacement therapy in a placebo-controlled, double-blind trial
2000 · n-3 fatty acid-enriched oil supplement · Postmenopausal women, receiving or not receiving hormone replacement therapy
1.6 g4 weeks—
Moderate fish-oil supplementation reverses low-platelet, long-chain n-3 polyunsaturated fatty acid status and reduces plasma triacylglycerol concentrations in British Indo-Asians
2004 · Fish-oil group · British Indo-Asian Sikhs and Europeans; adults, age and weight matched between ethnic groups
1 g12 weeks—
Influence of an algal triacylglycerol containing docosahexaenoic acid (22 : 6n-3) and docosapentaenoic acid (22 : 5n-6) on cardiovascular risk factors in healthy men and women
2006 · Active treatment · Healthy men and women
1.5 g4 weeks—
Docosahexaenoic acid supply in pregnancy affects placental expression of fatty acid transport proteins
2006 · 500 mg DHA + 150 mg eicosapentaenoic acid · Healthy pregnant women during the second half of gestation
500 mg——
Arachidonic acid and docosahexaenoic acid supplementation increases coronary flow velocity reserve in Japanese elderly individuals
2008 · PUFA · Japanese elderly individuals, mean age 65 years; no condition stated
240 mg90 days—
Influence of a concentrated ethylester compound of n-3 fatty acids on lipids, platelets and coagulation in patients undergoing coronary bypass surgery
1991 · n-3 fatty acids · Patients eligible for coronary bypass surgery with fasting triglyceride levels of at least 1.6 mmol/L
1.89 g26 weeks—
Decreased cord blood IL-4, IL-13, and CCR4 and increased TGF-beta levels after fish oil supplementation of pregnant women
2008 · fish oil (FO) · pregnant women; age and health condition not specified
500 mg——
Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study
2008 · n-3 FAs group · Alzheimer disease patients
1.7 g26 weeks—
Fish oil supplementation lowers C-reactive protein levels independent of triglyceride reduction in patients with end-stage renal disease
2009 · fish oil group · Patients with end-stage renal disease; age range and sex not reported
600 mg26 weeks—
Effect of n-3 oral supplements on the n-6/n-3 ratio in young adults
2010 · experimental group · healthy young adults
1.2 g4 weeks—
Th1 and Th2 chemokines, vaccine-induced immunity, and allergic disease in infants after maternal ω-3 fatty acid supplementation during pregnancy and lactation
2011 · ω-3 fatty acid supplementation · Pregnant women at risk of having an allergic infant
1.1 g——
ALOX5 gene variants affect eicosanoid production and response to fish oil supplementation
2011 · fish oil · African American adults aged 20–59 years, 68% female; no specific condition stated
1 g——
[Effect on the lipid profile of diet supplemented with fish oil concentrate]
1990 · n-3 treated group · male and female patients with cholesterol values higher than 7.0 mmol/l
1.5 g12 weeks—
Fish oil supplementation in early infancy modulates developing infant immune responses
2012 · fish oil group · Infants of high atopic risk, from birth; sex not specified
280 mg26 weeks—
Efficacy of omega-3 fatty acid supplementation on serum levels of tumour necrosis factor-alpha, C-reactive protein and interleukin-2 in type 2 diabetes mellitus patients
2012 · treatment group · Adults aged 45–85 years with type 2 diabetes mellitus for at least two years
828 mg8 weeks—
Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load
2012 · n-3 PUFAs · Patients with combined dyslipidemia; age and sex not specified
1.35 g26 weeks—
Eicosapentaenoic and docosahexaenoic acid supplementations reduce platelet aggregation and hemostatic markers differentially in men and women
2013 · DHA-rich oil capsules · Healthy men and women
1 g4 weeks—
Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial
2013 · group 1 · Individuals with nonexudative age-related macular degeneration; age and sex not specified
100 mg1 year—
Effect of n-3 supplementation on hyperactivity, oxidative stress and inflammatory mediators in children with attention-deficit-hyperactivity disorder
2012 · n-3 group · Children aged 6–12 years with ADHD receiving maintenance therapy
195 mg8 weeks—
Effect of docosahexaenoic acid supplementation on inflammatory cytokine levels in infants at high genetic risk for type 1 diabetes
2015 · DHA treatment group (Groups A and B) · Infants with a first-degree relative with type 1 diabetes and HLA DR3 and/or DR4, or multiple first-degree relatives with type 1 diabetes; Group A treatment began in the last trimester of pregnancy and Group B treatment began in the first five postnatal months
1.2 g3 years—
Omega-3 fatty acids' effect on leptin and adiponectin concentrations in patients with spinal cord injury: A double-blinded randomized clinical trial
2015 · treatment group · Patients with spinal cord injury; age and sex not stated
930 mg426 days—
Effect of omega-3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial
2014 · eicosapentaenoic acid-docosahexaenoic acid plus α-linolenic acid group · Patients aged 60–80 years with a history of myocardial infarction; 81% were men.
159 mg1200 days—
Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study
2015 · n-3 FA treatment · Patients with Alzheimer's disease
1.7 g26 weeks—
Effects of Iron Supplementation With and Without Docosahexaenoic Acid on the Cardiovascular Disease Risk Based on Paraoxonase-1, hs-CRP, and ApoB/ApoA-I Ratio in Women with Iron Deficiency Anemia
2016 · DHA supplement with iron tablet · Women aged 15–45 years with iron deficiency anemia
500 mg12 weeks—
The Pattern of Fatty Acids Displaced by EPA and DHA Following 12 Months Supplementation Varies between Blood Cell and Plasma Fractions
2015 · 1 portion per week · Healthy non-oily-fish-consuming adults; age range and sex distribution not stated
253 mg1 year—
The effect of 12-wk ω-3 fatty acid supplementation on in vivo thalamus glutathione concentration in patients "at risk" for major depression
2015 · ω-3 FA supplements · Older adults at risk for depression; age range and sex not specified
800 mg12 weeks—
A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease
2017 · krill oil · People with mild to moderate dry eye disease; age and sex not reported
510 mg90 days—
A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease
2017 · fish oil · People with mild to moderate dry eye disease; age and sex not reported
500 mg90 days—
Effect of diets rich in either saturated fat or n-6 polyunsaturated fatty acids and supplemented with long-chain n-3 polyunsaturated fatty acids on plasma lipoprotein profiles
2017 · SFA-rich diet · Healthy subjects; age and sex not reported
2 g6 weeks—
Effect of diets rich in either saturated fat or n-6 polyunsaturated fatty acids and supplemented with long-chain n-3 polyunsaturated fatty acids on plasma lipoprotein profiles
2017 · n-6PUFA-rich diet · Healthy subjects; age and sex not reported
2 g6 weeks—
Effects of postnatal omega-3 fatty acid supplementation on offspring pro-resolving mediators of inflammation at 6 months and 5 years of age: A double blind, randomized controlled clinical trial
2017 · omega-3 fatty acid group · Infants from birth to 6 months of age
280 mg26 weeks—
Comparison of Omega-3 Eicosapentaenoic Acid Versus Docosahexaenoic Acid-Rich Fish Oil Supplementation on Plasma Lipids and Lipoproteins in Normolipidemic Adults
2020 · EPA-rich fish oil · Healthy adults aged 23–44, without chronic or serious disease
1.5 g8 weeks—
Comparison of Omega-3 Eicosapentaenoic Acid Versus Docosahexaenoic Acid-Rich Fish Oil Supplementation on Plasma Lipids and Lipoproteins in Normolipidemic Adults
2020 · DHA-rich fish oil · Healthy adults aged 23–44, without chronic or serious disease
3.6 g8 weeks—
Evaluation of Cognitive Performance following Fish-Oil and Curcumin Supplementation in Middle-Aged and Older Adults with Overweight or Obesity
2020 · fish oil · Adults aged 50–80 years with overweight or obesity (BMI 25–40 kg/m²)
2 g16 weeks—
The Impacts of Fish Oil and/or Probiotic Intervention on Low-Grade Inflammation, IGFBP-1 and MMP-8 in Pregnancy: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial
2020 · fish oil + placebo · Overweight or obese pregnant women at increased risk for gestational diabetes
1.9 g——
The Impacts of Fish Oil and/or Probiotic Intervention on Low-Grade Inflammation, IGFBP-1 and MMP-8 in Pregnancy: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial
2020 · fish oil + probiotics · Overweight or obese pregnant women at increased risk for gestational diabetes
1.9 g——
Modification of subcutaneous white adipose tissue inflammation by omega-3 fatty acids is limited in human obesity-a double blind, randomised clinical trial
2022 · Fish oil · Adults aged 18–65 years, healthy normal-weight participants and participants living with obesity without diagnosed metabolic complications
800 mg12 weeks—
Eicosapentaenoic and docosahexaenoic acid supplementation and coronary artery calcium progression in patients with coronary artery disease: A secondary analysis of a randomized trial
2023 · EPA + DHA · Adults aged 37–80 years with stable coronary artery disease
1.5 g900 days—
The Effect of Eicosapentaenoic and Docosahexaenoic Acid Supplementation on Coronary Artery Calcium Progression in Subjects With Diabetes and Coronary Artery Disease: A Secondary Analysis of a Randomized Trial
2024 · EPA+DHA supplementation · Adults with coronary artery disease on statin therapy, with and without diabetes
1.5 g913 days—
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
2025 · AREDS2 DHA plus EPA · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye
350 mg5 years—
Effects of fish oil on plasma fibrinolysis in patients with mild rheumatoid arthritis
1995 · fish oil treatment group · Patients with mild rheumatoid arthritis; age and sex not reported
1.1 g26 weeks—
Fish diet, fish oil and docosahexaenoic acid rich oil lower fasting and postprandial plasma lipid levels
1996 · fish oil group · Healthy male university students
950 mg15 weeks—
Fish diet, fish oil and docosahexaenoic acid rich oil lower fasting and postprandial plasma lipid levels
1996 · DHA-oil group · Healthy male university students
5.68 g15 weeks—
Use of a Micronutrient Cocktail to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Adults with Obesity: A Randomized, Double-Blinded Pilot Clinical Trial
2024 · intervention group · Adults aged 18–70 with obesity and dyslipidemia
280 mg90 days105
A Mixed Flavonoid-Fish Oil Supplement Induces Immune-Enhancing and Anti-Inflammatory Transcriptomic Changes in Adult Obese and Overweight Women-A Randomized Controlled Trial
2016 · Q-Mix · Women aged 40–70 years who were overweight or obese (BMI ≥25 kg/m²), without the listed major diseases
90 mg10 weeks24
Synbiotic Bacillus megaterium DSM 32963 and n-3 PUFA Salt Composition Elevates Pro-Resolving Lipid Mediator Levels in Healthy Subjects: A Randomized Controlled Study
2024 · SynΩ3 group · Healthy men and women aged 30–75 years, selected as at-risk individuals with omega-3 index ≤6.5% and elevated AGEs and/or hsCRP
83.4 mg4 weeks24
The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer's disease: results from a randomized controlled trial
2017 · Test product (Souvenaid/Fortasyn Connect) · Adults aged 50 years or older with mild probable or possible Alzheimer’s disease
1.2 g4 weeks16
The immunomodulatory effects of fish-oil supplementation in elite paddlers: A pilot randomized double blind placebo-controlled trial
2015 · fish-oil capsules · male elite paddlers undertaking an increasing exercise program
1.2 g4 weeks11
Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration
2014 · Group 1 (Vitalux plus Omega-3) · Adults with active wet age-related macular degeneration who had previously received anti-VEGF treatment
200 mg—10
A 16-week randomized placebo-controlled trial investigating the effects of omega-3 polyunsaturated fatty acid treatment on white matter microstructure in recent-onset psychosis patients concurrently treated with risperidone
2021 · risperidone + FO · Patients aged 15–40 with recent-onset psychosis, including schizophrenia-spectrum disorders or bipolar disorder
400 mg16 weeks10
Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye
2011 · omega-3 group · Patients with dry eye; age and sex not reported
300 mg90 days—
Reproductive state and choline intake influence enrichment of plasma lysophosphatidylcholine-DHA: a post hoc analysis of a controlled feeding trial
2019 · 480 mg choline per day group · Healthy non-pregnant, third-trimester pregnant, and lactating women; reproductive groups were included in the analysis
200 mg12 weeks—
Synbiotic Bacillus megaterium DSM 32963 and n-3 PUFA Salt Composition Elevates Pro-Resolving Lipid Mediator Levels in Healthy Subjects: A Randomized Controlled Study
2024 · Fish oil group · Healthy men and women aged 30–75 years, selected as at-risk individuals with omega-3 index ≤6.5% and elevated AGEs and/or hsCRP
120 mg4 weeks—
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
2025 · AREDS2 lutein/zeaxanthin plus DHA/EPA · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye
350 mg5 years—
The effect of curcumin and high-content eicosapentaenoic acid supplementations in type 2 diabetes mellitus patients: a double-blinded randomized clinical trial
2024 · Group (2) / EP (EPA plus placebo) · Adults aged 18 years or older with type 2 diabetes and HbA1c >5.8%; mean age 56.40 years; men and women
400 mg12 weeks25
The effect of curcumin and high-content eicosapentaenoic acid supplementations in type 2 diabetes mellitus patients: a double-blinded randomized clinical trial
2024 · Group (3) / CE (curcumin plus EPA) · Adults aged 18 years or older with type 2 diabetes and HbA1c >5.8%; mean age 56.40 years; men and women
400 mg12 weeks25
Evaluation of Cognitive Performance following Fish-Oil and Curcumin Supplementation in Middle-Aged and Older Adults with Overweight or Obesity
2020 · combination · Adults aged 50–80 years with overweight or obesity (BMI 25–40 kg/m²)
2 g16 weeks—
Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study
2019 · PUFA supplementation alone · Adults aged 70 years or older with a memory complaint, an instrumental activity limitation, or slow walking speed
800 mg3 years401
Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study
2019 · PUFA supplementation + multidomain intervention · Adults aged 70 years or older with a memory complaint, an instrumental activity limitation, or slow walking speed
800 mg3 years399
Effect of docosahexaenoic acid-enriched fish oil supplementation in pregnant women with Type 2 diabetes on membrane fatty acids and fetal body composition--double-blinded randomized placebo-controlled trial
2014 · fish oil, healthy women · Healthy pregnant women
600 mg—45
Decreased cord blood IL-4, IL-13, and CCR4 and increased TGF-beta levels after fish oil supplementation of pregnant women
2008 · fish oil (FO) and methyl-tetra-hydrofolic acid · pregnant women; age and health condition not specified
500 mg——
Omega-3 fatty acids ameliorate vascular inflammation: A rationale for their atheroprotective effects
2021 · DHA · healthy volunteers
4 g30 days—